Your browser is no longer supported. Please, upgrade your browser.
Settings
AZN AstraZeneca PLC daily Stock Chart
AZN [NYSE]
AstraZeneca PLC
Index- P/E21.88 EPS (ttm)1.38 Insider Own0.50% Shs Outstand2.53B Perf Week0.30%
Market Cap76.51B Forward P/E15.40 EPS next Y1.96 Insider Trans0.00% Shs Float2.50B Perf Month-3.39%
Income3.50B PEG2.92 EPS next Q0.40 Inst Own13.30% Short Float1.28% Perf Quarter15.29%
Sales23.00B P/S3.33 EPS this Y23.80% Inst Trans-0.11% Short Ratio6.14 Perf Half Y0.78%
Book/sh5.87 P/B5.15 EPS next Y7.27% ROA5.50% Target Price33.87 Perf Year5.18%
Cash/sh2.33 P/C12.96 EPS next 5Y7.50% ROE24.90% 52W Range24.73 - 33.47 Perf YTD14.36%
Dividend1.90 P/FCF- EPS past 5Y-17.60% ROI15.00% 52W High-9.65% Beta0.84
Dividend %6.28% Quick Ratio0.70 Sales past 5Y-7.30% Gross Margin82.60% 52W Low22.28% ATR0.36
Employees59700 Current Ratio0.90 Sales Q/Q-12.70% Oper. Margin21.30% RSI (14)49.81 Volatility0.83% 0.81%
OptionableYes Debt/Eq1.13 EPS Q/Q127.80% Profit Margin15.20% Rel Volume0.51 Prev Close29.76
ShortableYes LT Debt/Eq0.98 EarningsApr 27 BMO Payout32.50% Avg Volume5.20M Price30.24
Recom2.20 SMA20-1.07% SMA500.84% SMA2003.23% Volume2,642,645 Change1.61%
Apr-10-17Downgrade Jefferies Buy → Hold
Apr-05-17Downgrade UBS Buy → Neutral
Mar-09-17Initiated Liberum Buy
Dec-09-16Upgrade Leerink Partners Mkt Perform → Outperform
Nov-25-16Upgrade Liberum Hold → Buy
Sep-23-16Initiated Piper Jaffray Overweight
Sep-12-16Upgrade Jefferies Hold → Buy
Aug-29-16Upgrade Argus Hold → Buy
Jul-12-16Initiated Argus Hold
Apr-12-16Downgrade Goldman Neutral → Sell
Mar-15-16Downgrade Jefferies Buy → Hold
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-08-16Downgrade HSBC Securities Buy → Hold
Jan-19-16Upgrade Barclays Underweight → Equal Weight
Dec-01-15Upgrade Morgan Stanley Underweight → Overweight
Nov-02-15Downgrade Nordea Buy → Hold
Oct-20-15Downgrade Credit Suisse Neutral → Underperform
Sep-18-15Upgrade Bryan Garnier Neutral → Buy
Jul-31-15Upgrade Swedbank Neutral → Buy
Jul-02-15Upgrade Berenberg Hold → Buy
Apr-21-17 06:52AM  Tesaros Zejula Flops as H&S Pattern Emerges Investopedia
05:44AM  What to Expect From European Pharmaceuticals' First Quarter Results TheStreet.com
Apr-20-17 01:21PM  AbbVie's PARP Inhibitor Comes Up Empty Motley Fool
09:52AM  Group launching website to brand region as biotech leader American City Business Journals
Apr-18-17 07:27AM  [$$] Circassia halts allergy programme after failed trials Financial Times
Apr-10-17 04:25PM  Could Dow Stock Merck Undercut AstraZeneca In Lung Cancer? Investor's Business Daily
Apr-05-17 02:19PM  [$$] AstraZeneca under pressure amid caution over cancer drug trial Financial Times
02:19PM  [$$] AstraZeneca under pressure amid caution over cancer drug trial
02:09PM  The Mutual Fund That Is a Top 10 Guru GuruFocus.com
02:09PM  The Mutual Fund That Is a Top 10 Guru
12:54PM  Charts of the day: Amazon shares gain on NFL deal; Deutsche Bank calls boosts Caterpillar, United Rentals; AT&T adds HBO to unlimited plan Yahoo Finance
12:54PM  Charts of the day: Amazon shares gain on NFL deal; Deutsche Bank calls boosts Caterpillar, United Rentals; AT&T adds HBO to unlimited plan
Apr-04-17 04:48PM  Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst Investor's Business Daily
04:48PM  Bristol Keeps Up With Merck In Cancer, But Incyte Is True Winner: Analyst
Apr-03-17 11:15AM  Drug spun off by AstraZeneca shows promise in hot flashes Reuters
11:15AM  Drug spun off by AstraZeneca shows promise in hot flashes
09:50AM  AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval Zacks
09:50AM  AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
09:07AM  The Latest from Sanofis Diabetes and Cardiovascular Franchise
08:15AM  Blog Coverage AstraZeneca's Lung Cancer Drug Received Full Approval from FDA Accesswire
Apr-02-17 07:23AM  5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them Motley Fool
07:23AM  5 Deadliest Diseases in the U.S. -- and the Top Drugs Potentially on the Way to Treat Them at Motley Fool
Mar-31-17 04:12PM  FDA Approves Astra's Lung Cancer Drug Investopedia
04:12PM  FDA Approves Astra's Lung Cancer Drug at Investopedia
02:05PM  Consistent Performance Measurement May Improve Novartiss R&D
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
07:05AM  FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS GlobeNewswire
07:00AM  TAGRISSO® (osimertinib) Receives US FDA Full Approval Business Wire
05:23AM  Astrazeneca Scores Milestone Victory in Oncology
Mar-29-17 03:21PM  Keep Trading AstraZeneca From the Long Side
11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA
11:41AM  AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA at Investopedia
10:36AM  Performance of GlaxoSmithKlines HIV Business in 2016
09:21AM  Tesaro Nets Surprise Early Approval at Motley Fool
08:46AM  AstraZeneca's NMOSD Drug Gets EU Orphan Drug Status (AZN) at Investopedia
08:29AM  Tesaro wont reveal price of its ovarian cancer drug. But itll likely be near $14,000 a month at MarketWatch
Mar-28-17 06:03PM  Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula at Investopedia
03:42PM  Could Real-World Studies Boost These 3 Big Pharma Stocks' Prospects? at Motley Fool
12:18PM  Why Clovis' Advantage Might Squash Tesaro In Ovarian Cancer
10:10AM  Company News for March 28, 2017
09:49AM  Instant Analysis: Tesaro Receives a Big Thumbs-Up From the FDA at Motley Fool
09:00AM  New Data Demonstrate RSV Immunoprophylaxis With SYNAGIS® (palivizumab) May Result in Reduced Overall Costs in Preterm Infants Born at 29-32 wGA Who Are Less Than Three Months of Age Business Wire
07:00AM  AstraZeneca Shares Progress on LYNPARZA (olaparib) Tablets in the US Business Wire
04:15AM  Tesaro Secures FDA Nod for Ovarian Cancer Drug at Investopedia
Mar-27-17 08:44PM  First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks at Forbes
08:42PM  Tesaro wins FDA approval for potential blockbuster cancer drug at bizjournals.com
04:33PM  Tesaro Creeps Up On Rivals With Cancer Drug OK, But Merger Unlikely
04:07PM  Tesaro Secures Early and Broad Approval for PARP Inhibitor in Ovarian Cancer
10:08AM  AstraZeneca's Lung Cancer Drug Tagrisso Approved in China
06:06AM  AstraZenecas Lung Cancer Drug Secures China Approval (AZN) at Investopedia
Mar-24-17 11:51PM  New Lung Cancer Drug From AstraZeneca is Approved in China
Mar-23-17 10:59AM  AstraZeneca Stock Rising in '17: What's Working in its Favor?
Mar-22-17 10:37AM  Durvalumab and Tagrisso May Boost AstraZenecas Revenues in 2017
09:07AM  How AstraZeneca Controlled Operating Expenses in 2016
08:52AM  Novartis Heart Drug Fails Late Stage Trials (NVS, AZN) at Investopedia
07:38AM  What Will Drive AstraZenecas Oncology Revenues in 2017?
Mar-21-17 06:05PM  Japan May Prove to Be Strong Growth Driver for AstraZeneca in 2017
04:35PM  Why AstraZenecas Brilinta Could Become a Blockbuster Drug in 2017
02:36PM  What to Expect from AstraZenecas Farxiga in 2017
01:23PM  FDA Sends Complete Response Letter To AstraZeneca PLC (ADR) (AZN) Following Rejection Of Hyperkalemia Drug at Insider Monkey
12:42PM  Pulmatrix Inhaled Drug Delivery Tech Gets EU Patent at Investopedia
12:05PM  Understanding Ionis Pharmaceuticals 2016 Revenue Stream
Mar-20-17 08:13PM  AstraZeneca PLC (ADR) (AZN) In Respiratory Drug Deal With Circassia Pharmaceuticals at Insider Monkey
11:46AM  Why Nektar Therapeutics Inc. Is Rising Today at Motley Fool
11:35AM  Novel Diabetes Drugs Improve Heart Protection at Investopedia
10:32AM  AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
Mar-19-17 02:05PM  AstraZenecas CVD-REAL Study Shows SGLT-2 Inhibitors Significantly Reduced Hospitalizations for Heart Failure and Death versus Other Type-2 Diabetes Medicines Business Wire
Mar-17-17 12:52PM  Woodford-Backed Biopharma Stock Circassia Surges on Astra Pact
12:00PM  $230M deal: AstraZeneca forms COPD drugs collaboration at bizjournals.com
09:45AM  AstraZeneca Inks $230 Million COPD Drugs Deal at Investopedia
09:42AM  AstraZeneca (AZN): Should Value Investors Pick this Stock?
09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
07:21AM  FDA Rejects AstraZenecas Hyperkalemia Drug (AZN, RLYP) at Investopedia
05:22AM  AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment
Mar-16-17 02:49PM  AstraZeneca PLC (ADR) (AZN)s Lynparza Trial Results Positive In Competitive Threat To Clovis Oncology Inc (CLVS) And TESARO Inc (TSRO) at Insider Monkey
08:21AM  AstraZeneca Fires Back at Tesaro in Ovarian Cancer at Motley Fool
08:05AM  Life-Saving Device Could Transform The Medical Market In 2017
Mar-15-17 04:15PM  Tesaro Sell-Off On AstraZeneca Ovarian Cancer Trial Overdone: Analyst
03:47PM  AstraZeneca's Cancer Drug Lynparza Positive in Phase III
03:35PM  Biotech's PARP Wars Cool Down
02:53PM  Merck Could Be Nearing This Rival With Another Keytruda Approval
01:54PM  Heres What Just Happened With AstraZeneca PLC (ADR) (AZN), TESARO Inc (TSRO) And Clovis Oncology Inc (CLVS) at Insider Monkey
01:19PM  AstraZeneca Ovarian Cancer Drug Succeeds in Trial at Investopedia
11:16AM  7 Most Popular Diet Pills That Work Fast Without Exercise at Insider Monkey
08:32AM  Lynparza Vs. Niraparib
08:08AM  Clovis Shares Reiterated As A Sell Following 10% Rally
Mar-14-17 04:17PM  Tesaro Trips On AstraZeneca's Ovarian Cancer Trial While Clovis Climbs
04:09PM  Why Tesaro is Tanking at Barrons.com
03:43PM  AstraZeneca Takes PARP Inhibitor Fight to Rival Tesaro with Strong Ovarian Cancer Study Results
02:32PM  LYNPARZA (olaparib) Phase III SOLO-2 Data Demonstrated Progression-Free Survival Benefit in BRCA-Mutated Ovarian Cancer as Maintenance Therapy Business Wire
02:30PM  AstraZeneca ovarian cancer drug slows disease markedly in study
01:52PM  AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered at Insider Monkey
12:03AM  AstraZeneca Gives Rejected Drugs a Second Life at The Wall Street Journal
Mar-13-17 09:53AM  [$$] AstraZeneca Gives Rejected Drugs a Second Life at The Wall Street Journal
08:01AM  The Next Big Biotech Breakthrough Could Just Be On The Horizon
Mar-11-17 01:04PM  ASTRAZENECA PLC Financials
Mar-10-17 02:13PM  Dear Gilead: Buy Something Anything Analyst Pleads
12:52PM  Healthcare Giant's Profits Not As Large As They Appear at Forbes
Mar-09-17 10:28AM  Causeway International Value Buys AstraZeneca, Gildan
09:46AM  2 Dividend Stocks to Stay Away From -- and 1 Worth Buying at Motley Fool
AstraZeneca PLC engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. Its marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. It serves primary care and specialty care physicians through distributors and local representative offices. The company's pipeline includes 132 projects, of which 120 are in the clinical phase of development. It has collaboration agreements with Valeant Holdings Ireland, and Eli Lilly and Company; definitive agreement with Foundation Medicine, Inc.; strategic collaboration with FibroGen and Astellas; collaboration and license agreement with Celgene International Sarl; and license agreement with LEO Pharma A/S. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
EBAY eBay Inc. daily Stock Chart
EBAY [NASD]
eBay Inc.
IndexS&P 500 P/E4.57 EPS (ttm)7.01 Insider Own6.70% Shs Outstand1.12B Perf Week-6.94%
Market Cap36.00B Forward P/E14.50 EPS next Y2.21 Insider Trans-0.53% Shs Float998.58M Perf Month-4.39%
Income7.84B PEG0.62 EPS next Q0.45 Inst Own87.10% Short Float1.54% Perf Quarter5.88%
Sales9.06B P/S3.97 EPS this Y299.00% Inst Trans0.15% Short Ratio1.66 Perf Half Y10.44%
Book/sh10.71 P/B2.99 EPS next Y10.16% ROA35.10% Target Price35.15 Perf Year31.35%
Cash/sh6.01 P/C5.33 EPS next 5Y7.37% ROE88.30% 52W Range22.30 - 34.74 Perf YTD7.95%
Dividend- P/FCF16.64 EPS past 5Y21.00% ROI30.60% 52W High-7.74% Beta1.31
Dividend %- Quick Ratio1.90 Sales past 5Y-5.10% Gross Margin77.40% 52W Low43.72% ATR0.63
Employees12600 Current Ratio1.90 Sales Q/Q3.70% Oper. Margin24.90% RSI (14)29.72 Volatility2.00% 1.63%
OptionableYes Debt/Eq0.77 EPS Q/Q128.20% Profit Margin86.30% Rel Volume1.78 Prev Close32.18
ShortableYes LT Debt/Eq0.58 EarningsApr 19 AMC Payout0.00% Avg Volume9.30M Price32.05
Recom2.50 SMA20-5.00% SMA50-4.72% SMA2003.21% Volume16,552,506 Change-0.40%
Apr-20-17Reiterated Canaccord Genuity Hold $31 → $32
Apr-20-17Downgrade Monness Crespi & Hardt Buy → Neutral
Apr-13-17Reiterated Aegis Capital Buy $38 → $40
Mar-29-17Initiated Barclays Overweight $41
Mar-29-17Initiated Barclays Overweight
Feb-17-17Resumed Pacific Crest Sector Weight
Jan-26-17Reiterated Stifel Hold $31 → $35
Jan-26-17Reiterated RBC Capital Mkts Sector Perform $32 → $34
Jan-26-17Reiterated Aegis Capital Buy $36 → $38
Jan-24-17Reiterated The Benchmark Company Buy $39 → $37
Jan-03-17Resumed Piper Jaffray Neutral $28
Jan-03-17Initiated Aegis Capital Buy $36
Oct-21-16Upgrade Hilliard Lyons Long-term Buy → Buy
Oct-20-16Reiterated Wedbush Neutral $34 → $33
Oct-20-16Reiterated Mizuho Neutral $31 → $32
Oct-18-16Reiterated Monness Crespi & Hardt Buy $32 → $35
Oct-17-16Reiterated The Benchmark Company Buy $33 → $38
Oct-13-16Resumed Wedbush Neutral $34
Sep-29-16Upgrade Deutsche Bank Hold → Buy $30 → $40
Sep-14-16Reiterated Axiom Capital Buy $34 → $38
Apr-24-17 10:19AM  eBay, Inc. :EBAY-US: Earnings Analysis: Q1, 2017 By the Numbers : April 24, 2017 Capital Cube
Apr-23-17 08:16PM  Labor calls for delay of GST collection on low-value imports ZDNet
Apr-21-17 11:26AM  eBay Slumps Despite Q1 Beat: Buy the Dip via ETFs? Zacks
09:13AM  eBay, Inc. breached its 50 day moving average in a Bearish Manner : EBAY-US : April 21, 2017 Capital Cube
08:00AM  Edited Transcript of EBAY earnings conference call or presentation 19-Apr-17 9:00pm GMT Thomson Reuters StreetEvents
12:53AM  ATO fails to rule out website blocking to enforce online GST collection ZDNet
Apr-20-17 04:39PM  Analysts See 250 Million Apple iPhone Shipments, Amazon Stock At 1,000 Investor's Business Daily
04:20PM  EBay Breaks 2 Key Technical Levels Despite Analyst Cheerleading Investor's Business Daily
04:17PM  AmEx Kicks Off Wall Street Rally, Mnuchin Tax Comments Keep it Going TheStreet.com
03:40PM  EBay analysts await big changes before diving in MarketWatch
03:15PM  Stocks Solidly Higher as Amex Earnings Fuel Good Vibes Over Reporting Season TheStreet.com
12:30PM  What Analysts Are Saying About eBay After Earnings 24/7 Wall St.
11:27AM  [$$] EBay Results Beat Expectations The Wall Street Journal
10:57AM  Amex Does Heavy Lifting on Dow, S&P 500 After Positive Earnings TheStreet.com
10:55AM  eBay (EBAY) Beats Earnings and Revenue Estimates in Q1 Zacks
10:48AM  Jim Cramer's Take on eBay, Whether to Buy Disney for ESPN TheStreet.com
09:55AM  Cramer's Stop Trading: DIS & EBAY CNBC Videos
09:00AM  Story Stocks from Briefing.com Briefing.com
08:41AM  Stock Futures Rise on Positive Earnings From Amex, Qualcomm TheStreet.com
08:22AM  Solid Start, Back-Half Tailwinds Support View on Ebay Morningstar
07:30AM  Investor Focus Shifts to Earnings Season: Today's Research Reports on eBay and American Express Accesswire
05:59AM  5 Things You Must Know Before the Market Opens Thursday TheStreet.com
12:39AM  Stocks Slide With Oil Prices The Wall Street Journal
12:31AM  Stock Futures Lean Higher: Can Dow Find Support? Investor's Business Daily
Apr-19-17 08:16PM  eBay Inc. Delivers Another Solid Quarter Motley Fool
07:18PM  EBay's second-quarter profit forecast falls short of estimates Reuters
06:24PM  Amazon vs eBay: Which should you buy? CNBC Videos
06:08PM  EBay, American Express, Qualcomm, CSX Move On Late Earnings Investor's Business Daily
06:07PM  eBay (EBAY) Posts Q1 Earnings Beat, Revenue Climbs 4% Zacks
05:47PM  eBay's Q1 beats expectations, shares slip on soft guidance ZDNet
05:03PM  EBay Delivers Mixed Earnings Benzinga
05:01PM  eBay Earnings Not Enough to Balance Out Weak Guidance 24/7 Wall St.
05:00PM  EBay Meets Revenue Forecast, Beats On Earnings Investor's Business Daily
04:57PM  EBay Struggles With Turnaround as Goliath Amazon Holds Sway Bloomberg
04:49PM  Ebay forecasts 2nd-qtr profit below estimates Reuters
04:39PM  eBay Slips: Q1 Revenue, EPS Beat; Q2 View Light; Affirms Year Outlook Barrons.com
04:36PM  EBay stock falls 2% after quarterly earnings MarketWatch
04:36PM  eBay Stock Tumbling After Latest Earnings TheStreet.com
04:35PM  Ebay Q1 GMV $20.9B CNBC Videos
04:34PM  EBay tops Street 1Q forecasts Associated Press
04:30PM  EBay Meets Revenue Forecast, Beats On Earnings Investor's Business Daily
04:15PM  eBay Inc. Reports First Quarter 2017 Results PR Newswire
02:59PM  Britain loses one billion pounds through VAT fraud and error by Amazon and eBay sellers Reuters
02:48PM  Britain loses 1 bln stg through VAT fraud and error by Amazon and eBay sellers Reuters
01:14PM  A Fine Rookie Year for This Retail ETF Investopedia
12:46PM  S&P 500 Stabilizes as Investors Parse Earnings Reports The Wall Street Journal
12:08PM  Earnings: Ebay And Verizon Set To Report Q1 Benzinga
11:32AM  Earnings Preview: eBay Focuses On Transformation And Verizon Goes Unlimited Forbes
08:00AM  [$$] EBay Earnings: What to Watch The Wall Street Journal
07:19AM  EBay earnings: in-line first quarter expected, but threats ahead MarketWatch
07:07AM  5 Things You Must Know Before the Market Opens Wednesday TheStreet.com
12:29AM  Futures: Dow Faces 62-Point Drag But These 2 E-Commerce Giants Are In Buy Range Investor's Business Daily
Apr-18-17 04:15PM  What To Expect When eBay Reports First-Quarter Earnings Investor's Business Daily
02:21PM  Items To Focus On When eBay Reports Q1 Results This Week Benzinga
01:17PM  PayPal and Google Partner for Digital Wallet Investopedia
01:10PM  4 Top Earnings to Look For on Wednesday 24/7 Wall St.
10:29AM  eBay (EBAY) to Report Q1 Earnings: Is a Surprise in Store? Zacks
09:30AM  Zacks Investment Ideas feature highlights: IBM, Lam Research, eBay and NCR Zacks
08:17AM  Earnings Preview: What To Expect From eBay On Wednesday Forbes
Apr-17-17 08:20PM  What to Watch When eBay Reports Earnings Motley Fool
01:07PM  This Week In Tech Stocks Zacks
Apr-15-17 09:45AM  7 Key Earnings Expected This Coming Week 24/7 Wall St.
Apr-14-17 01:11PM  Competition Heats Up in This Massive E-Commerce Market Motley Fool
Apr-13-17 04:19PM  Aspiring tech prodigy tries to re-route self-driving cars Associated Press
08:35AM  Aspiring tech prodigy tries to re-route self-driving cars Associated Press
Apr-12-17 04:54PM  More bad news for brick-and-mortar retail: Teenagers' changing spending habits American City Business Journals
01:55PM  Jeff Bezos: Nobody asked for one of our most popular services Yahoo Finance
01:40PM  Bulls bid on eBay & one energy name CNBC Videos
10:03AM  Flipkart Raises $1.4B Fresh Fund to Compete with Amazon Zacks
09:00AM  StubHub Introduces New Social Tools To Make Planning, Organizing and Attending Events More Engaging PR Newswire
Apr-11-17 01:46PM  How Amazon Will Be Affected By Flipkart's Recent Moves Forbes
12:19AM  [$$] Microsoft, eBay, Tencent Invest $1.4 Billion in Amazons India Rival The Wall Street Journal
Apr-10-17 10:20PM  Tencent Leads $1.4 Billion Investment in India's Flipkart Barrons.com
06:36PM  EBay Backs Flipkart With $500M to Battle Amazon in India Bloomberg Video
02:24PM  This Amazon Rival Just Got $1.4 Billion From eBay, Microsoft, & Tencent Zacks
10:01AM  India's Flipkart raises $1.4 billion in high stakes battle with Amazon Reuters
08:40AM  [$$] Microsoft, eBay, Tencent Invest $1.4 Billion in Amazon's India Rival The Wall Street Journal
07:55AM  India's Flipkart Raises $1.4 Billion to Combat Amazon Expansion TheStreet.com
07:12AM  Flipkart raises a record $1.4 billion to take on Amazon in India Quartz
06:54AM  India's Flipkart raises $1.4 bln in high stakes battle with Amazon Reuters
05:49AM  India's Flipkart raises $1.4 bln from Tencent, eBay, Microsoft Reuters
05:03AM  eBay and Flipkart Sign Exclusive Agreement to Jointly Address the eCommerce Market Opportunity in India PR Newswire
Apr-08-17 06:21PM  The Best Dividend Stock in E-Commerce Motley Fool
Apr-07-17 01:52PM  11 Worst Tech Mergers and Acquisitions Ever Insider Monkey
08:51AM  EBay The Latest Big Name To Plan Snapchat Content Campaign Benzinga
03:17AM  Why Is eBay Inc(EBAY) Up 5.9% Since the Last Earnings Report? Zacks
Apr-04-17 06:23PM  Why Shopify is a Great Growth Stock TheStreet.com
06:23PM  Why Shopify is a Great Growth Stock
09:07AM  Alibaba Is Learning from eBay about Navigating Payments Market Market Realist
09:07AM  Alibaba Is Learning from eBay about Navigating Payments Market
Mar-31-17 03:25PM  Facebook crowdfunding launch could boost its only declining business at MarketWatch
10:18AM  BARCLAYS: eBay could see a big turnaround in 2017 Business Insider
10:18AM  BARCLAYS: eBay could see a big turnaround in 2017
Mar-30-17 01:08PM  Coty Argues For Brand Protection, Not a Restriction of Online Sales
11:05AM  Amazon Stock Hits a Fresh High: What's Driving the Increase? Investopedia
11:05AM  Amazon Stock Hits a Fresh High: What's Driving the Increase?
10:31AM  Coty says not against online sales, wants to protect luxury brands Reuters
10:30AM  Toronto Blue Jays Reach Agreement with StubHub to Become the Club's Official Ticket Resale Marketplace PR Newswire
10:30AM  Toronto Blue Jays Reach Agreement with StubHub to Become the Club's Official Ticket Resale Marketplace CNW Group
12:00AM  [$$] How to bid successfully at an auction at Financial Times
eBay Inc. operates commerce platforms that connect various buyers and sellers worldwide. Its platforms enable sellers to organize and offer their inventory for sale; and buyers to find and purchase it virtually. The company's Marketplace platforms include its online marketplace at ebay.com and the eBay mobile apps; and StubHub platforms comprise its online ticket platform at stubhub.com, and the StubHub mobile apps and Ticketbis platforms that connect fans with their favorite sporting events, shows, and artists, as well as enables them to buy and sell tickets. Its Classifieds platforms include a collection of brands, such as mobile.de, Kijiji, Gumtree, Marktplaats, eBay Kleinanzeigen, and others, which offer online classifieds to enable people find whatever they are looking for in their local communities. The company's platforms enable users to find, buy, sell, and pay for items through various online, mobile, and offline channels that include retailers, distributors, liquidators, import and export companies, auctioneers, catalog and mail-order companies, classifieds, directories, search engines, commerce participants, shopping channels, and networks. eBay Inc. was founded in 1995 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WENIG DEVINPresident and CEOApr 01Option Exercise0.0061,3920495,684Apr 03 08:32 PM
Doerger Brian J.VP, Chief Accounting OfficerApr 01Option Exercise0.0025,323057,174Apr 03 08:30 PM
Yetto Kristin ASVP, Chief People OfficerApr 01Option Exercise0.0012,903058,243Apr 03 08:26 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerApr 01Option Exercise0.0010,9730106,002Apr 03 08:23 PM
Lee Jae HyunSVP, Asia PacificApr 01Option Exercise0.0012,4280118,605Apr 04 08:54 PM
Schenkel Scott F.Chief Financial OfficerApr 01Option Exercise0.0019,4930109,778Apr 04 08:36 PM
Todd Jeremy PaulSVP, EMEAApr 01Option Exercise0.0017,168092,294Apr 04 08:29 PM
FISHER STEPHENSVP, CTOApr 01Option Exercise0.0010,9190110,533Apr 03 08:36 PM
Huber Marie OhSVP, GC and SecretaryMar 15Option Exercise0.002,501042,811Mar 17 06:51 PM
Todd Jeremy PaulSVP, EMEAMar 15Option Exercise0.002,084076,232Mar 17 06:49 PM
Doerger Brian J.VP, Chief Accounting OfficerMar 15Option Exercise0.004,559033,565Mar 17 06:46 PM
Schenkel Scott F.Chief Financial OfficerMar 15Option Exercise0.006,252093,548Mar 17 06:43 PM
Lawton III Harry ASVP, North AmericaMar 15Option Exercise0.003,647038,350Mar 17 06:41 PM
Lee Jae HyunSVP, Asia PacificMar 15Option Exercise0.003,1260106,177Mar 17 06:38 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerMar 15Option Exercise0.005,731098,020Mar 17 06:35 PM
FISHER STEPHENSVP, CTOMar 15Option Exercise0.007,2940103,421Mar 17 06:32 PM
Yetto Kristin ASVP, Chief People OfficerMar 15Option Exercise0.003,126046,972Mar 17 06:29 PM
WENIG DEVINPresident and CEOMar 15Option Exercise0.0013,0860441,121Mar 17 06:26 PM
Huber Marie OhSVP, GC and SecretaryMar 01Option Exercise0.0037,870040,310Mar 03 07:06 PM
Lee Jae HyunSVP, Asia PacificMar 01Option Exercise0.0026,2040103,051Mar 03 06:59 PM
Yetto Kristin ASVP, Chief People OfficerMar 01Option Exercise0.0049,538058,198Mar 03 06:48 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerMar 01Option Exercise0.0032,7540111,597Mar 03 06:26 PM
FISHER STEPHENSVP, CTOMar 01Option Exercise0.0045,8560135,543Mar 03 06:02 PM
Todd Jeremy PaulSVP, EMEAMar 01Option Exercise0.0013,103081,212Mar 03 07:24 PM
Lawton III Harry ASVP, North AmericaMar 01Option Exercise0.0037,870052,390Mar 03 07:12 PM
Lee Jae HyunSVP, Asia PaificFeb 27Sale33.986,375216,62976,847Mar 01 05:08 PM
Lawton III Harry ASVP, North AmericaFeb 23Sale33.7313,400451,92214,520Feb 27 07:49 PM
FISHER STEPHENSVP, CTOFeb 22Option Exercise21.6416,543358,02199,657Feb 23 06:33 PM
FISHER STEPHENSVP, CTOFeb 22Sale33.7716,601560,62189,687Feb 23 06:33 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerFeb 17Option Exercise23.0810,974253,27885,966Feb 21 07:40 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerFeb 17Sale33.6630,0101,010,00477,879Feb 21 07:40 PM
Lee Jae HyunSVP, Asia PacificFeb 16Sale34.118,000272,88483,222Feb 21 07:35 PM
Doerger Brian J.VP, Chief Accounting OfficerFeb 09Sale33.256,660221,43229,006Feb 10 05:21 PM
TIERNEY THOMAS JDirectorFeb 08Option Exercise9.856,01459,23828,525Feb 09 07:38 PM
Lee Jae HyunSVP, eBay Marketplaces AsiaFeb 08Option Exercise22.6253,1271,201,614117,972Feb 10 05:15 PM
Lee Jae HyunSVP, eBay Marketplaces AsiaFeb 08Sale32.7853,1271,741,57291,222Feb 10 05:15 PM
TIERNEY THOMAS JDirectorFeb 08Sale33.286,014200,15722,511Feb 09 07:38 PM
SWAN ROBERT HOLMESDirectorJan 30Option Exercise22.69125,6082,850,288442,401Jan 31 06:03 PM
SWAN ROBERT HOLMESDirectorJan 30Sale32.00200,6086,418,532301,633Jan 31 06:03 PM
Yetto Kristin ASVP, Chief People OfficerDec 15Option Exercise0.003,126023,966Dec 16 07:57 PM
FISHER STEPHENSVP, CTODec 15Option Exercise0.007,294093,552Dec 16 07:51 PM
WENIG DEVINPresident and CEODec 15Option Exercise0.0013,0860472,666Dec 16 07:47 PM
Schenkel Scott F.Chief Financial OfficerDec 15Option Exercise0.006,2520104,017Dec 19 07:48 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerDec 15Option Exercise0.00137,6430169,703Dec 19 07:38 PM
Lee Jae HyunSVP, Asia PacificDec 15Option Exercise0.003,126091,222Dec 19 07:32 PM
Doerger Brian J.VP, Chief Accounting OfficerDec 15Option Exercise0.0018,487045,313Dec 19 07:28 PM
Lawton III Harry ASVP, North AmericaDec 15Option Exercise0.003,647029,824Dec 19 07:23 PM
Huber Marie OhSVP, GC and SecretaryDec 15Option Exercise0.002,501022,079Dec 19 07:17 PM
Todd Jeremy PaulSVP, EMEADec 15Option Exercise0.002,084069,233Dec 19 07:09 PM
Doerger Brian J.VP, Chief Accounting OfficerNov 21Option Exercise22.8818,000411,87644,826Nov 23 07:13 PM
Doerger Brian J.VP, Chief Accounting OfficerNov 21Sale28.9318,000520,79626,826Nov 23 07:13 PM
Green LoganDirectorNov 02Buy28.321,00028,3211,000Nov 03 08:02 PM
FISHER STEPHENSVP, CTOOct 25Option Exercise21.6412,408268,532120,563Oct 26 07:50 PM
FISHER STEPHENSVP, CTOOct 25Sale29.2039,7641,161,10986,258Oct 26 07:50 PM
FISHER STEPHENSVP, CTOOct 15Option Exercise0.00106,5490169,212Oct 17 06:42 PM
Schenkel Scott F.SVP, Chief Financial OfficerOct 15Option Exercise0.005,9070100,848Oct 17 06:37 PM
WENIG DEVINPresident and CEOOct 15Option Exercise0.0013,8980466,832Oct 17 06:32 PM
Yetto Kristin ASVP, Chief People OfficerSep 15Option Exercise0.003,126022,472Sep 19 06:23 PM
Todd Jeremy PaulSVP, EMEASep 15Option Exercise0.002,084068,280Sep 19 06:06 PM
Schenkel Scott F.SVP, Chief Financial OfficerSep 15Option Exercise0.006,252098,204Sep 19 06:00 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerSep 15Option Exercise0.005,731035,051Sep 19 05:54 PM
Lee Jae HyunSVP, Asia PacificSep 15Option Exercise0.003,126088,096Sep 19 05:49 PM
Lawton III Harry ASVP, North AmericaSep 15Option Exercise0.003,647028,081Sep 19 05:44 PM
Huber Marie OhSVP, GC and SecretarySep 15Option Exercise0.002,500020,883Sep 19 05:32 PM
FISHER STEPHENSVP, CTOSep 15Option Exercise0.007,294066,470Sep 19 05:22 PM
Doerger Brian J.VP, Chief Accounting OfficerSep 15Option Exercise0.004,558029,205Sep 19 05:16 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerAug 31Option Exercise22.7141,880951,13948,779Sep 01 05:49 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerAug 31Sale32.1439,0301,254,56526,980Sep 01 05:49 PM
Lee Jae HyunSVP, Asia PacificAug 31Sale31.8516,559527,42684,970Sep 02 04:58 PM
SWAN ROBERT HOLMESDirectorAug 30Sale31.9550,0001,597,500375,928Sep 01 05:27 PM
Lee Jae HyunSVP, Asia PacificAug 24Sale31.025,625174,488101,529Aug 26 06:40 PM
Todd Jeremy PaulSVP, EMEAAug 10Option Exercise0.0032,935084,065Aug 12 05:06 PM
Lee Jae HyunSVP, Asia PacificJul 27Sale31.533,222101,590107,154Jul 28 08:15 PM
Lee Jae HyunSVP, Asia PacificJul 26Sale31.0310,601328,949110,376Jul 27 06:40 PM
Doerger Brian J.VP, Chief Accounting OfficerJul 25Option Exercise22.6313,608307,94948,605Jul 27 06:19 PM
FISHER STEPHENSVP, CTOJul 25Option Exercise21.6437,223805,57797,032Jul 27 06:58 PM
TIERNEY THOMAS JDirectorJul 25Option Exercise9.858,00078,80025,545Jul 27 07:13 PM
SWAN ROBERT HOLMESDirectorJul 25Sale30.6550,0001,532,340425,288Jul 27 07:06 PM
FISHER STEPHENSVP, CTOJul 25Sale30.6553,3891,636,16959,176Jul 27 06:58 PM
TIERNEY THOMAS JDirectorJul 25Sale30.658,000245,20017,545Jul 27 07:13 PM
Lee Jae HyunSVP, Asia PacificJul 25Sale30.741,16735,878120,977Jul 27 06:40 PM
Yetto Kristin ASVP, Chief People OfficerJul 25Sale30.7917,596541,83419,346Jul 27 06:34 PM
Doerger Brian J.VP, Chief Accounting OfficerJul 25Sale30.5623,958732,26424,647Jul 27 06:19 PM
Schenkel Scott F.SVP, Chief Financial OfficerJul 17Option Exercise0.001,768092,875Jul 18 08:27 PM
WENIG DEVINPresident and CEOJul 17Option Exercise0.005,8950449,754Jul 18 07:55 PM
Lawton III Harry ASVP, N.A.Jun 15Option Exercise0.0042,723039,075Jun 17 07:57 PM
Lee Jae HyunSVP, Asia PacificJun 15Option Exercise0.003,1270122,144Jun 17 07:53 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerJun 15Option Exercise0.005,732029,461Jun 17 07:50 PM
Doerger Brian J.VP, Chief Accounting OfficerJun 15Option Exercise0.004,559037,376Jun 17 07:46 PM
Todd Jeremy PaulSVP, EMEAJun 15Option Exercise0.0014,501057,098Jun 17 07:42 PM
WENIG DEVINPresident and CEOJun 15Option Exercise0.0013,0870450,688Jun 17 08:18 PM
Schenkel Scott F.SVP, Chief Financial OfficerJun 15Option Exercise0.006,253094,370Jun 17 08:15 PM
Huber Marie OhSVP, GC & SecretaryJun 15Option Exercise0.0031,556029,055Jun 17 08:10 PM
Yetto Kristin ASVP, Chief People OfficerJun 15Option Exercise0.0015,543041,926Jun 17 08:04 PM
FISHER STEPHENSVP, CTOJun 15Option Exercise0.007,295079,149Jun 16 08:42 PM
Doerger Brian J.VP, Chief Accounting OfficerJun 08Option Exercise0.0011,388038,760Jun 09 05:22 PM
PITTMAN RAYMOND JSVP, Chief Product OfficerMay 27Sale24.2425,000605,89823,729Jun 01 04:28 PM
Doerger Brian J.VP, Chief Accounting OfficerMay 24Option Exercise16.6814,474241,42641,846May 24 08:58 PM
Doerger Brian J.VP, Chief Accounting OfficerMay 24Sale24.0814,474348,53427,372May 24 08:58 PM
Doerger Brian J.VP, Chief Accounting OfficerMay 09Option Exercise16.6820,000333,60047,372May 10 07:49 PM
EPD Enterprise Products Partners L.P. daily Stock Chart
EPD [NYSE]
Enterprise Products Partners L.P.
Index- P/E26.27 EPS (ttm)1.06 Insider Own0.30% Shs Outstand2.12B Perf Week0.36%
Market Cap59.09B Forward P/E17.80 EPS next Y1.57 Insider Trans0.35% Shs Float1.43B Perf Month2.92%
Income2.50B PEG3.69 EPS next Q0.33 Inst Own37.00% Short Float1.36% Perf Quarter0.04%
Sales23.02B P/S2.57 EPS this Y-20.90% Inst Trans0.02% Short Ratio4.74 Perf Half Y2.88%
Book/sh10.45 P/B2.67 EPS next Y11.39% ROA4.90% Target Price32.89 Perf Year2.01%
Cash/sh0.03 P/C932.10 EPS next 5Y7.13% ROE11.50% 52W Range24.01 - 30.25 Perf YTD3.00%
Dividend1.66 P/FCF- EPS past 5Y-3.30% ROI7.80% 52W High-7.93% Beta0.90
Dividend %5.96% Quick Ratio0.60 Sales past 5Y-12.30% Gross Margin14.70% 52W Low15.99% ATR0.36
Employees6800 Current Ratio0.80 Sales Q/Q5.30% Oper. Margin15.60% RSI (14)53.13 Volatility1.28% 1.33%
OptionableYes Debt/Eq1.07 EPS Q/Q-49.30% Profit Margin10.90% Rel Volume1.55 Prev Close27.68
ShortableYes LT Debt/Eq0.96 EarningsMay 02 BMO Payout132.30% Avg Volume4.09M Price27.85
Recom1.60 SMA200.96% SMA500.03% SMA2002.33% Volume6,332,324 Change0.61%
Apr-18-17Initiated Guggenheim Buy
Jan-31-17Reiterated Barclays Overweight $31 → $33
Nov-16-16Initiated Ladenburg Thalmann Buy
Sep-30-16Initiated Mizuho Buy $32
Sep-19-16Upgrade Credit Suisse Neutral → Outperform
Aug-31-16Reiterated Wunderlich Buy $33 → $32
Aug-18-16Downgrade Morgan Stanley Overweight → Equal-Weight
May-11-16Initiated Bernstein Outperform $33
Apr-29-16Downgrade Seaport Global Securities Buy → Neutral $30
Jan-20-16Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-06-16Initiated Scotia Howard Weil Sector Outperform $31
Nov-03-15Reiterated Argus Buy $44 → $38
Jul-31-15Reiterated Stifel Buy $38 → $34
Jul-23-15Initiated DA Davidson Buy $36
Jun-16-15Initiated Sun Trust Rbsn Humphrey Buy
May-19-15Initiated Wunderlich Buy $38
May-19-15Initiated Deutsche Bank Buy $38
Jan-20-15Reiterated Oppenheimer Outperform $44 → $39
Jun-03-14Initiated Global Hunter Securities Buy $83
May-02-14Reiterated Stifel Buy $75 → $78
Apr-24-17 05:35PM  What EPDs Low Implied Volatility Means for Its Stock Price Market Realist
04:05PM  Will Enterprise Products Partners Stock Gain Strength? Market Realist
02:06PM  Despite Oils Plunge, Enterprise Products Closed the Week Flat Market Realist
Apr-21-17 07:37AM  Kinder Morgans 1Q17 Net Income Falls 9%, Misses Estimates Market Realist
Apr-20-17 11:46AM  EnLink Midstream Partners Implied Volatility Rose the Most Market Realist
11:06AM  Better Buy: Enterprise Products Partners L.P. vs. Buckeye Partners, L.P. Motley Fool
07:36AM  What Does ONEOKs Current Valuation Indicate? Market Realist
Apr-18-17 05:05PM  How Williams Partners Expects to Benefit from Geismar Plant Sale Market Realist
10:37AM  What Does Kinder Morgans Valuation Indicate? Market Realist
Apr-17-17 08:15AM  Blog Coverage ConocoPhillips Nets $3 Billion from Sale of San Juan Basin Assets to Hilcorp Energy Accesswire
Apr-15-17 09:16AM  2 Top Dividend Stocks for Low-Risk Investors Motley Fool
Apr-13-17 11:08AM  Love Dividends? Here's 4 Energy Sector Stocks You Might Want to Buy Motley Fool
10:00AM  I Still Can't Believe Enterprise Products Partners L.P. Spent $189 million on This Bankrupt Company Motley Fool
Apr-12-17 01:23PM  Enterprise Products Partners LP Value Analysis (NYSE:EPD) : April 12, 2017 Capital Cube
08:58AM  Enterprise Sets Record for Volumes at Texas Gulf Coast Marine Terminals Business Wire
Apr-11-17 10:46AM  Enterprise to Build 571 Mile Pipeline from Permian Basin Zacks
10:11AM  2 Energy Stocks I'd Buy Right Now Motley Fool
08:20AM  Enterprise Products Partners LP breached its 50 day moving average in a Bullish Manner : EPD-US : April 11, 2017 Capital Cube
07:37AM  Is Enterprise Products Partners Fairly Valued? Market Realist
Apr-10-17 03:05PM  Analyzing Short Interest in Enterprise Products Partners Stock Market Realist
02:15PM  Enterprise Products Partners to build 571-mile NGL pipeline American City Business Journals
01:35PM  What to Expect from Enterprise Products Partners Stock Market Realist
12:00PM  Is Enterprise Products Partners Stock Gaining Strength? Market Realist
11:59AM  Enterprise Products Partners Raised Its 1Q17 Distribution Market Realist
08:30AM  Enterprise to Build Shin Oak NGL Pipeline from Permian Basin to Mont Belvieu, Texas Business Wire
Apr-08-17 12:00PM  Top Fracking Stocks to Buy in 2017 Motley Fool
Apr-07-17 02:39PM  Enterprise Products Partners: Look for a Resolution to the Upside TheStreet.com
07:24AM  In the midst of an oil-price slump, one area in Texas is enjoying a bit of a boom MarketWatch
Apr-06-17 02:36PM  MLPs with the Maximum Potential Upside after 1Q17 Market Realist
10:09AM  Enterprise Products Announces Quarterly Distribution Hike Zacks
08:24AM  3 Stocks We'd Buy and Hold for the Next 20 Years Motley Fool
06:26AM  [$$] Why the Texas natural gas boom is making waves Financial Times
Apr-05-17 08:51AM  Enterprise Declares Quarterly Distribution Increase Business Wire
Apr-04-17 04:20PM  Houston company to build ethylene storage, pipeline projects American City Business Journals
10:29AM  Enterprise Products Partners to Expand Ethylene Projects Zacks
07:37AM  Is ONEOK Stock Fairly Valued? Market Realist
Apr-03-17 02:33PM  These 6 Energy Names Are Big Holdings of the Most MLP Funds Barrons.com
12:05PM  Kinder Morgan Stock Gains Strength, but Can It Keep It Up? Market Realist
08:30AM  Enterprise to Develop Ethylene Storage and Transportation Projects Business Wire
Mar-31-17 12:14PM  5 Things You Didn't Know About Enterprise Products Partners L.P. Motley Fool
08:30AM  Enterprise Products Partners to Participate in Mizuho Energy Infrastructure Conference Business Wire
Mar-29-17 12:13PM  3 Top Dividend Stocks in Energy to Buy Now at Motley Fool
07:37AM  Analysts Recommendations for ONEOK
07:35AM  EPD: When Will the Oil Market Likely Balance?
Mar-28-17 06:00PM  The Wealthiest Oil & Gas Billionaires In The U.S.
02:36PM  ONEOK Is Trading near Its Historical Average
10:37AM  Analysts Recommendations for Enterprise Products Partners
09:05AM  What Does Short Interest in EPD Stock Indicate?
07:35AM  Are Institutional Investors Selling Their Holdings in EPD?
Mar-27-17 04:35PM  Is Kinder Morgans Current Valuation Attractive?
10:36AM  Analyzing Enterprise Products Partners Valuation
09:06AM  Why Enterprise Products Partners Leverage Isnt a Concern
07:37AM  Enterprise Products Partners Focuses on Petrochemicals
Mar-24-17 10:36AM  What Will Drive Enterprise Products Partners Growth?
09:29AM  Enterprise Products Partners to Participate in Scotia Howard Weil Energy Conference Business Wire
09:06AM  Retaining Cash Flows Helped Enterprise Products Partners
07:36AM  Why Enterprise Products Partners Focuses on Organic Growth
Mar-23-17 03:35PM  Enterprise Products Partners Increases Its NGL Export Volumes
02:05PM  Enterprise Products Partners: Key Player in US LPG Exports
12:33PM  Analyzing Enterprise Products Partners Business Segments
12:33PM  Enterprise Products Partners Extensive Asset Footprint
12:33PM  Whats Ahead for Enterprise Products Partners Stock?
Mar-22-17 07:37AM  What Does ONEOKs Current Valuation Indicate?
07:36AM  Is Kinder Morgan Attractively Valued?
Mar-21-17 10:41AM  Better Buy: Kinder Morgan, Inc. vs. Enterprise Products Partners L.P. at Motley Fool
10:24AM  Weakness in ONEOK Continues, Stock Fell 2.8% Last Week
08:36AM  The 3 Best Stocks to Profit From Low Interest Rates While They Last at Motley Fool
Mar-20-17 02:05PM  Why MLPs Continue to Be Attractive
Mar-18-17 10:32AM  Hate Risk? You'll Love These 2 Dividend Stocks at Motley Fool
08:10AM  Like Big Dividends? The I Bet You'll Love These 3 Stocks at Motley Fool
Mar-17-17 10:54AM  Enterprise Products Partners LP : EPD-US: Dividend Analysis : January 31st, 2017 (record date) : By the numbers : March 17, 2017
07:35AM  Is Enbridge Energy Partners Attractively Valued?
Mar-16-17 10:00AM  Can This 10% Dividend Even Survive? at Motley Fool
09:35AM  Houston energy co. wins midstream assets in bankruptcy auction at bizjournals.com
Mar-15-17 03:43PM  [$$] Enterprise Products Partners Buying Assets of Azure Midstream at The Wall Street Journal
01:36PM  Enterprise Acquires Azure Natural Gas Gathering System Business Wire
08:31AM  The 5 Best Dividend Stocks of 2027 at Motley Fool
Mar-14-17 03:32PM  Top Natural Gas Stocks to Buy in 2017 at Motley Fool
09:07AM  Is Williams Companies Currently Undervalued?
Mar-13-17 04:22PM  [$$] Azure Midstream's Assets Fetch $189 Million at Auction at The Wall Street Journal
11:25AM  Enterprise Products Partners Favored by Analysts at Investopedia
10:37AM  A Look at MLPs with an Attractive Potential Upside
Mar-10-17 05:07PM  Are MLPs Still Undervalued?
04:23PM  Better Pipeline Dividend Stock Buy: Kinder Morgan or Enterprise Products?
Mar-09-17 09:44AM  4 High-Yield Dividend Stocks You Don't Have to Babysit at Motley Fool
07:24AM  Enterprise (EPD) Closes Seaway Pipeline After Potential Leak
Mar-07-17 04:35PM  What Williams Companies Current Valuation Indicates
10:42AM  Which Midstream Stocks Have the Highest Implied Volatility?
09:20AM  3 Energy Stocks We Can't Help but Love at Motley Fool
08:00AM  Enterprise Products Partners to Host Analyst Day Business Wire
Mar-06-17 03:41PM  Enterprise Products Partners' Seaway pipeline shut after leak -traders
11:23AM  Enterprise Products Partners' Seaway pipeline shut after leak: traders
Mar-02-17 01:04PM  ENTERPRISE PRODUCTS PARTNERS L P Financials
07:38AM  What Analysts Recommend for ONEOK after 4Q16 Results
Mar-01-17 12:39PM  ONEOKs 4Q16 Earnings: Effect of Natural Gas, NGL Volumes
Feb-27-17 08:00AM  Enterprise Products Partners to Participate in Investor Conferences Business Wire
Feb-24-17 01:10PM  2016 K-1 Tax Packages for Enterprise Products Partners L.P. Business Wire
11:05AM  ENTERPRISE PRODUCTS PARTNERS L P Files SEC form 10-K, Annual Report
10:09AM  Enterprise Products Partners L.P. 2016 Form 10-K Now Available Business Wire
Feb-23-17 04:15PM  Enterprise Signs Natural Gas Processing Agreements with Producers from Wyomings Green River Basin Business Wire
Enterprise Products Partners L.P. provides midstream energy services to producers and consumers of natural gas, natural gas liquids (NGLs), crude oil, petrochemicals, and refined products. The company operates through NGL Pipelines & Services, Crude Oil Pipelines & Services, Natural Gas Pipelines & Services, and Petrochemical & Refined Products Services segments. The NGL Pipelines & Services segment offers natural gas processing and related NGL marketing services, as well as NGL export docks and related services. It operates approximately 19,670 miles of NGL pipelines; NGL and related product storage facilities; 15 NGL fractionators; and a liquefied petroleum gas and ethane export terminals, and related operations. The Crude Oil Pipelines & Services segment operates approximately 5,400 miles of crude oil pipelines and related operations; and crude oil storage and marine terminals located in Oklahoma and Texas, as well as a fleet of 440 tractor-trailer tank trucks used to transport crude oil. It also engages in crude oil marketing activities. The Natural Gas Pipelines & Services segment operates approximately 19,120 miles of natural gas pipeline systems to gather and transport natural gas in Colorado, Louisiana, New Mexico, Texas, and Wyoming. It leases underground salt dome natural gas storage facilities in Texas and Louisiana; owns an underground salt dome storage cavern in Texas; and markets natural gas. The Petrochemical & Refined Products Services segment operates propylene fractionation and related operations, including 686 miles of pipelines; butane isomerization complex, associated deisobutanizer units, and related pipeline assets; and octane enhancement and high purity isobutylene production facilities. It also operates approximately 4,250 miles of refined products pipelines; and terminals, as well as provides refined products marketing and marine transportation services. The company was founded in 1968 and is based in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Edwin EAdvisory DirectorMar 06Sale28.0215,000420,300420,654Mar 06 05:18 PM
HACKETT JAMES TDirectorFeb 03Buy28.6533,000945,45033,000Feb 06 04:14 PM
BARTH CARIN MARCYDirectorNov 16Buy25.274,000101,08013,126Nov 16 04:50 PM
VRX Valeant Pharmaceuticals International, Inc. daily Stock Chart
VRX [NYSE]
Valeant Pharmaceuticals International, Inc.
Index- P/E- EPS (ttm)-6.92 Insider Own2.30% Shs Outstand346.24M Perf Week-9.28%
Market Cap2.98B Forward P/E1.84 EPS next Y4.67 Insider Trans-69.97% Shs Float338.25M Perf Month-20.81%
Income-2409.00M PEG- EPS next Q0.91 Inst Own66.80% Short Float13.58% Perf Quarter-38.53%
Sales9.67B P/S0.31 EPS this Y-714.90% Inst Trans20.32% Short Ratio2.47 Perf Half Y-61.02%
Book/sh9.01 P/B0.95 EPS next Y19.00% ROA-5.20% Target Price- Perf Year-76.10%
Cash/sh1.57 P/C5.49 EPS next 5Y12.95% ROE-52.70% 52W Range8.36 - 38.50 Perf YTD-40.77%
Dividend- P/FCF1.66 EPS past 5Y61.43% ROI-1.60% 52W High-77.66% Beta-0.09
Dividend %- Quick Ratio1.10 Sales past 5Y31.90% Gross Margin73.00% 52W Low2.87% ATR0.40
Employees21500 Current Ratio1.40 Sales Q/Q-12.20% Oper. Margin-5.90% RSI (14)22.14 Volatility4.97% 3.88%
OptionableYes Debt/Eq9.47 EPS Q/Q-41.70% Profit Margin-24.90% Rel Volume0.84 Prev Close8.51
ShortableYes LT Debt/Eq9.47 EarningsMay 09 BMO Payout- Avg Volume18.60M Price8.60
Recom3.00 SMA20-13.22% SMA50-28.83% SMA200-53.94% Volume15,661,824 Change1.06%
Apr-20-17Reiterated JP Morgan Neutral $15 → $10
Mar-23-17Reiterated RBC Capital Mkts Sector Perform $21 → $18
Mar-06-17Reiterated Rodman & Renshaw Neutral $23 → $17
Feb-27-17Reiterated Mizuho Underperform $11 → $9
Feb-14-17Reiterated RBC Capital Mkts Sector Perform $29 → $22
Feb-10-17Reiterated Barclays Equal Weight $34 → $20
Jan-04-17Reiterated Piper Jaffray Underweight $16 → $11
Dec-15-16Downgrade Morgan Stanley Overweight → Equal-Weight $25 → $17
Nov-23-16Downgrade Mizuho Neutral → Underperform $25 → $11
Nov-14-16Reiterated Deutsche Bank Hold $29 → $24
Nov-10-16Reiterated Morgan Stanley Overweight $42 → $25
Nov-10-16Downgrade Rodman & Renshaw Buy → Neutral $81 → $23
Nov-09-16Reiterated RBC Capital Mkts Sector Perform $35 → $29
Oct-14-16Reiterated Deutsche Bank Hold $30 → $29
Oct-12-16Reiterated RBC Capital Mkts Sector Perform $36 → $35
Sep-20-16Resumed Deutsche Bank Hold $30
Aug-17-16Upgrade Morgan Stanley Equal-Weight → Overweight $33 → $42
Aug-15-16Upgrade Mizuho Underperform → Neutral $11 → $25
Aug-10-16Reiterated RBC Capital Mkts Sector Perform $31 → $36
Aug-10-16Reiterated Piper Jaffray Underweight $19 → $22
Apr-24-17 04:04PM  Rite Aid, DryShips Stumble into Mondays 52-Week Low Club 24/7 Wall St.
08:15AM  Blog Coverage: Valeant Announces the Pricing for SILIQ as the Lowest Priced Injectable Biologic for Moderate-To-Severe Plaque Psoriasis Accesswire
Apr-23-17 09:40AM  The Scariest Prescription Drug Price Chart You'll Ever See Motley Fool
Apr-22-17 02:12PM  Why Now Is Not the Time to Buy Valeant Pharmaceuticals Motley Fool
Apr-21-17 04:43PM  Valeant Shares Plummet as Debt Issues Remain Unsolved, Prices New Psoriasis Drug TheStreet.com
04:27PM  Why Valeant Pharmaceuticals, Manhattan Associates, and NCR Slumped Today Motley Fool
01:36PM  1 Current and 1 Former Healthcare CEO Who Deserve Far More Flak Than United Airlines' Oscar Munoz Motley Fool
12:28PM  Valeant Pharmaceuticals: Not Worth the Risk! Barrons.com
11:26AM  Jim Cramer -- Valeant's Not Worth the Speculation TheStreet.com
09:55AM  Cramer's Stop Trading: Valeant CNBC Videos
09:36AM  Valeant prices psoriasis treatment at $3,500 per month Reuters
07:53AM  Valeant prices psoriasis treatment at $3,500 per month Reuters
07:46AM  Valeant says its plaque psoriasis drug will cost $3,500 a month MarketWatch
07:30AM  Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis PR Newswire
Apr-20-17 10:34AM  Valeant: Will Earnings Even Matter? Barrons.com
08:36AM  4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings Zacks
Apr-19-17 07:30AM  Today's Research Reports on Stocks to Watch: Teva Pharmaceutical and Valeant Pharmaceuticals Accesswire
07:00AM  [$$] Investors bet on Incyte drug success Financial Times
Apr-18-17 10:00AM  How Drug-Company 'Benevolence' Silences the Sick Bloomberg -5.59%
Apr-13-17 10:21AM  Valeant Pharmaceuticals' Market Cap Is Now Lower Than Its Projected Full-Year EBITDA Motley Fool
Apr-10-17 05:00PM  Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call PR Newswire
05:00PM  Valeant Pharmaceuticals Announces 2017 Annual Meeting Of Shareholders Webcast And Q1 2017 Financial Results Conference Call CNW Group
01:00AM  Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views TheStreet.com
Apr-09-17 03:55PM  Valeant: It's Not a Game of Chess - Part IV GuruFocus.com
Apr-07-17 04:04PM  Valeant, DryShips Stuck in Fridays 52-Week Low Club 24/7 Wall St.
01:41PM  Why Valeant Just Popped Barrons.com
10:25AM  Valeant Shares on Pace to Finish Week at Lowest Level Since 2008 TheStreet.com
08:15AM  Blog Coverage Valeant's Bausch + Lomb Receives FDA Clearance for Vision Enhancement System Accesswire
Apr-06-17 04:04PM  Valeant, DryShips Dont Escape Thursdays 52-Week Low Club 24/7 Wall St.
09:49AM  Valeant's Merry-Go-Round of Disappointment Won't Stop Bloomberg
09:23AM  Can Valeant Pharmaceuticals Regain Its Mojo? Motley Fool
07:30AM  Bausch + Lomb Receives 510(k) Clearance From FDA For Stellaris Elite Next-Generation Phacoemulsification Platform PR Newswire
Apr-05-17 04:19PM  Valeant trades in below $10 for first time since 2008 CNBC -6.59%
04:04PM  Valeant, DryShips Plunge into Wednesdays 52-Week Low Club 24/7 Wall St.
04:03PM  Valeant Shares Close Below $10 for First Time Since 2008 TheStreet.com
01:53PM  Valeant (VRX) Stock Continues to Slump: Should You Buy the Dip? Zacks
12:59PM  Valeant Pharmaceuticals Is In Hat-Size Territory Investopedia
12:46PM  Valeant Tumbles Below $10 on Struggle to Sell Assets, Raise Cash Bloomberg
11:18AM  Valeant (VRX) Faces Pricing Issues, Generic Threats Loom Zacks
09:57AM  Why Valeant is Crashing Barrons.com
Apr-04-17 03:41PM  4 Reasons Valeant Pharmaceuticals Int'l Inc. Nosedived 23% in March Motley Fool
03:25PM  Moody's Liquidity-Stress Index dips again in March; markets remain supportive of US speculative-grade companies Moody's
01:55PM  Valeant Plummets After Revealing Jaw-Dropping Payday for Its CEO
Apr-03-17 12:50PM  Valeant: It Is Not a Game of Chess - Part III -5.08%
10:42AM  Valeant Pharmaceuticals Still Searches for a Bottom
08:00AM  Bill Ackman Just Gave Up on Valeant. Should You Too? at Motley Fool
Mar-31-17 06:15PM  Bill Ackman's Mea Culpa Cited These 3 Factors for Valeant's Downfall at Motley Fool
07:40AM  Why Is Valeant (VRX) Down 17.7% Since the Last Earnings Report?
Mar-30-17 09:10PM  Cenovus Falls After Conoco Deal, Valeant Resumes Decline: Most Active Stocks, March 30
04:43PM  Ackman to hedge fund clients: 'Deeply and profoundly sorry' for Valeant at bizjournals.com
03:07PM  Why Its So Hard for Activist Investors to Find Value
02:47PM  Ackman Reflects on His Valeant Investment
01:45PM  Bill Ackman Releases Annual Letter, Apologizes for Losing All That Money
12:35PM  Bill Ackman Apologizes for Valeant Investment Error
12:35PM  Bill Ackman Apologizes for Valeant Investment Error at Investopedia
10:48AM  Valeant Pharmaceuticals International, Inc -- Moody's raises Valeant's SGL to SGL-2; affirms existing ratings; negative outlook at Moody's
10:13AM  Pershing Square's Bill Ackman is Really, Really, Really Sorry at Barrons.com
09:58AM  Ackman Says He's Sorry For Valeant Investment
09:09AM  The Ultimate Kick in the Pants: Valeant's Former CEO Is Suing the Company at Motley Fool
08:55AM  Bill Ackman To Investors: 'Deeply And Profoundly' Sorry For The Valeant Fiasco
08:51AM  What Makes Valeant Pharmaceuticals (VRX) a Strong Sell?
08:51AM  What Makes Valeant Pharmaceuticals (VRX) a Strong Sell? at Investopedia
07:30AM  Bausch + Lomb ULTRA® for Astigmatism Contact Lenses Introduced PR Newswire
07:27AM  Bill Ackman apologizes for $4 billion Valeant mistake (finally) at MarketWatch
07:09AM  5 Things You Must Know Before the Market Opens Thursday
Mar-29-17 07:32PM  Valeant Investment Was a 'Huge Mistake' at Investopedia
06:27PM  Ackman apologizes for Valeant losses, calls bet a mistake
04:16PM  Ackman Is 'Profoundly' Sorry for $4 Billion Valeant 'Mistake'
03:47PM  Here's the Bill Ackman apology Wall Street's been waiting for
12:58PM  Valeant's Banks Extend a Lifeline
11:46AM  Shares of Valeant Rise as 2018 Debt Maturities Extended at Barrons.com
10:40AM  Roundtable: 1 Stock I Wont Touch With a 10-Foot Pole at Motley Fool
10:40AM  3 Stocks We Won't Touch With a 10-Foot Pole at Motley Fool
08:43AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock?
08:43AM  Are Options Traders Betting on a Big Move in Valeant Pharmaceuticals (VRX) Stock? at Investopedia
Mar-28-17 05:54PM  Behind the Bill Ackman Controversies
05:30PM  VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial
11:07AM  Orexigen Inks Commercialization Deal for Contrave, Stock Up
09:12AM  Former Valeant CEO Files Suit Against the Company
Mar-27-17 08:52PM  Valeant Ex-CEO Pearson Sues Drugmaker Over Withheld Shares
06:42PM  Former Valeant CEO sues company over unmade compensation -WSJ Reuters
06:02PM  [$$] Valeant Former CEO Sues Company Over Unmade Payments at The Wall Street Journal
12:43PM  TransDigm: The End is Nigh? at Barrons.com
09:30AM  Drug Manufacturers Continue to be Plagued by Pricing Concerns: Today's Research Reports on Valeant Pharmaceuticals and Mylan Accesswire
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
Mar-25-17 02:01PM  Can You Guess Which Drugmaker Has the Most Debt? (Hint: It's Not Valeant) at Motley Fool
Mar-24-17 05:45PM  Johnson & Johnson's CEO Believes Trump Is Missing the Point on Drug-Price Reform at Motley Fool
01:52PM  Francis Chou Comments on Valeant
01:48PM  Chou Opportunity Fund 4th Quarter Message to Shareholders
10:35AM  Bausch & Lomb Continues to be Key Growth Driver for Valeant
09:05AM  Valeants Diversified Products Revenue May Drop in 2017
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
Mar-23-17 09:15PM  The 'Dogs' of Wall Street: Here's a Look at Some of the Worst Performing Stocks of the Year
02:47PM  A Safer Way to Play Valeant and Community Health at Barrons.com
11:05AM  'Female Viagra' founder: GOP health bill would hurt the 'sexual revolution'
10:49AM  Valeant CEO Compensation Revealed, Shares Climb
10:35AM  Siliq May be a Strong Growth Driver for Valeant in 2017
10:26AM  Bill Ackman Is Back at the Sohn Investment Conference This Year at The Wall Street Journal
10:16AM  Valeant: Room to Move? at Barrons.com
09:06AM  New Product Launches May Boost Valeants Dermatology Revenue
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The company offers Lotemax gel for the treatment of inflammation and pain following ocular surgery; Ocuvite, a lutein eye vitamin and mineral supplement; PreserVision, an antioxidant eye vitamin and mineral supplement; ReNu Multiplus products; Biotrue multi-purpose solution for healthy contact lens wear; Artelac to treat dry eyes; Boston, a cleansing solution for gas permeable contact lenses; and Bedoyecta, a vitamin B complex. It also provides SofLens daily disposable contact lenses; ophthalmic surgical products; PureVision, a silicone hydrogel; Biotrue ONEday daily disposable contact lenses; Bausch + Lomb Ultra, a silicone hydrogel replacement contact lens; and medical device systems. In addition, the company offers Xifaxan for the treatment of irritable bowel syndrome; Provenge for the treatment of prostate cancer; Uceris to get ulcerative colitis under control; Arestin, a subgingival sustained-release antibiotic; Jublia for the treatment of onychomycosis; Solodyn for the treatment of acne; Elidel to treat skin conditions; and Glumetza tablets to enhance glycemic control. Further, it provides Wellbutrin XL for the treatment of major depressive disorder; Isuprel injections; Xenazine for the treatment of chorea; Nitropress for the reduction of blood pressure of patients in hypertensive crises; Cuprimine to treat Wilson's disease; Zegerid to treat certain stomach and esophagus problems; Tobramycin and Dexamethasone ophthalmic suspension for steroid responsive inflammatory ocular conditions; and Latanoprost medicines to treat a type of glaucoma. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September, 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DE SCHUTTER RICHARD UDirectorMar 15Buy10.8010,000108,00025,190Mar 16 05:12 PM
Herendeen PaulEVP and CFOMar 14Buy10.7224,000257,280174,000Mar 16 05:04 PM
ValueAct Holdings, L.P.DirectorMar 14Buy10.823,000,00032,465,00016,937,431Mar 16 04:31 PM
Pershing Square Capital ManageDirectorMar 13Sale11.0018,114,432199,258,7520Mar 14 04:14 PM
Ross Thomas W. Sr.DirectorDec 14Buy14.735,00073,65026,822Dec 16 04:19 PM
Pershing Square Capital ManageDirectorDec 12Sale14.853,476,69051,628,84718,114,432Dec 13 04:14 PM
KARABELAS ARGERIS NDirectorAug 11Buy24.654,00098,60020,726Aug 12 04:37 PM
Ross Thomas W. Sr.DirectorJun 13Buy24.404,00097,60021,882Jun 27 03:40 PM
PAPA JOSEPH CCHAIRMAN & CEOJun 10Buy24.48202,0004,944,9602,442,199Jun 13 06:47 AM
LYB LyondellBasell Industries N.V. daily Stock Chart
LYB [NYSE]
LyondellBasell Industries N.V.
IndexS&P 500 P/E9.50 EPS (ttm)9.11 Insider Own0.10% Shs Outstand402.87M Perf Week1.45%
Market Cap34.86B Forward P/E9.44 EPS next Y9.16 Insider Trans-91.97% Shs Float323.84M Perf Month-2.02%
Income3.84B PEG- EPS next Q2.36 Inst Own76.50% Short Float2.64% Perf Quarter-4.22%
Sales29.18B P/S1.19 EPS this Y-4.70% Inst Trans0.18% Short Ratio3.10 Perf Half Y8.11%
Book/sh14.86 P/B5.82 EPS next Y-9.00% ROA16.30% Target Price98.33 Perf Year-1.21%
Cash/sh5.02 P/C17.24 EPS next 5Y-2.76% ROE61.90% 52W Range68.51 - 96.76 Perf YTD1.78%
Dividend3.40 P/FCF17.71 EPS past 5Y16.00% ROI24.60% 52W High-10.58% Beta1.05
Dividend %3.93% Quick Ratio1.30 Sales past 5Y-9.50% Gross Margin20.50% 52W Low26.29% ATR1.65
Employees13000 Current Ratio2.10 Sales Q/Q9.60% Oper. Margin17.40% RSI (14)41.45 Volatility1.47% 1.98%
OptionableYes Debt/Eq1.48 EPS Q/Q9.70% Profit Margin13.10% Rel Volume0.79 Prev Close85.42
ShortableYes LT Debt/Eq1.39 EarningsApr 28 BMO Payout36.60% Avg Volume2.75M Price86.52
Recom2.50 SMA20-1.85% SMA50-3.68% SMA2003.66% Volume2,174,485 Change1.29%
Feb-10-17Downgrade Susquehanna Positive → Neutral
Feb-06-17Reiterated RBC Capital Mkts Sector Perform $92 → $95
Dec-29-16Reiterated Cowen Market Perform $87 → $90
Oct-14-16Initiated Tudor Pickering Buy
Sep-13-16Reiterated Deutsche Bank Hold $80 → $83
Jun-27-16Downgrade RBC Capital Mkts Outperform → Sector Perform $100 → $84
Jun-23-16Downgrade JP Morgan Overweight → Neutral $100 → $80
Jun-13-16Downgrade Cowen Outperform → Market Perform $105 → $87
Apr-27-16Downgrade Nomura Buy → Neutral
Apr-05-16Downgrade Atlantic Equities Neutral → Underweight
Feb-03-16Downgrade RBC Capital Mkts Top Pick → Outperform $105 → $95
Jan-11-16Downgrade Credit Agricole Outperform → Underperform
Nov-25-15Reiterated Cowen Outperform $98 → $105
Oct-12-15Downgrade Macquarie Outperform → Neutral
Sep-17-15Reiterated Deutsche Bank Hold $100 → $95
Sep-11-15Initiated Bernstein Outperform $110
Sep-01-15Reiterated Cowen Outperform $115 → $98
May-08-15Initiated Standpoint Research Buy
Apr-28-15Reiterated RBC Capital Mkts Top Pick $111 → $123
Apr-27-15Reiterated Jefferies Hold $85 → $99
Apr-21-17 08:28PM  [$$] Judge Dismisses Most of Lyondell Bankruptcy Lawsuit The Wall Street Journal
08:27PM  [$$] Blavatnik cleared of fraud claims over Lyondell Chemical buyout Financial Times
10:50AM  What's in Store for Material ETFs in Q1 Earnings? Zacks
09:06AM  What Are Dow Chemicals Valuations ahead of 1Q17 Earnings? Market Realist
Apr-20-17 09:07AM  Why DuPont Trades at a Premium to Its Peers Market Realist
Apr-17-17 09:49AM  LyondellBasells ACP Polyethylene Technology to Be Used by Hengli Market Realist
Apr-14-17 11:30AM  LyondellBasell to Discuss First-Quarter Results on Friday, April 28, 2017 PR Newswire
Apr-05-17 09:29AM  Opening Bell, April 5, 2107 CNBC Videos
09:29AM  Opening Bell, April 5, 2107
Apr-03-17 11:20AM  LyondellBasell Industries NV : LYB-US: Dividend Analysis : March 06th, 2017 (record date) : By the numbers : April 3, 2017 Capital Cube
11:20AM  LyondellBasell Industries NV : LYB-US: Dividend Analysis : March 06th, 2017 (record date) : By the numbers : April 3, 2017
09:55AM  LyondellBasell Joins the Astros Foundation Community Leaders Program PR Newswire
Mar-31-17 08:55AM  See which Houston brands rank among the 500 most valuable in the U.S. this year at bizjournals.com
Mar-30-17 09:30AM  Zacks Industry Outlook Highlights: Dow Chemical, DuPont, PPG Industries, Celanese and LyondellBasell Industries Investopedia
09:30AM  Zacks Industry Outlook Highlights: Dow Chemical, DuPont, PPG Industries, Celanese and LyondellBasell Industries
09:07AM  Inside Eastman Chemicals Latest Valuations Market Realist
09:07AM  Inside Eastman Chemicals Latest Valuations
Mar-29-17 03:46PM  Chemicals Industry Stock Outlook - March 2017 Investopedia
03:46PM  Chemicals Industry Stock Outlook - March 2017
01:04PM  LyondellBasell to Host Investor Day 2017 on April 5, 2017 PR Newswire
10:00AM  Is LyondellBasell (LYB) a Great Stock for Value Investors? Zacks
10:00AM  Is LyondellBasell (LYB) a Great Stock for Value Investors?
10:00AM  Is LyondellBasell (LYB) a Great Stock for Value Investors? at Investopedia
Mar-23-17 07:37AM  Dow Chemical Trades at a Premium to Its Peers Market Realist
07:37AM  Dow Chemical Trades at a Premium to Its Peers
Mar-22-17 12:35PM  Dow Chemical Provides a Stable Dividend Yield
10:51AM  Dow Chemical Will Pay a Dividend of $0.46 in 1Q17
10:50AM  Analyzing How Dow Chemical Stock Has Performed in 2017
Mar-20-17 10:05AM  Shandong Yuhuang Shengshi Chemical Finalizes Deal with LYB
09:07AM  What Huntsmans Inconsistent Dividend Means to Investors
Mar-13-17 09:07AM  Can LyondellBasells Valuation Come Out of Its Peers Shadow?
07:37AM  LyondellBasell Gets Hold Rating from Majority of Analysts
Mar-10-17 01:05PM  How Attractive Is LyondellBasells Dividend Yield?
11:35AM  LyondellBasell Gears Up to Pay Its First Dividend in 2017
09:48AM  LyondellBasell Stock: 2017 Performance So Far
09:00AM  LyondellBasell Honored by Junior Achievement with US President's Volunteer Service Award PR Newswire
07:35AM  LyondellBasell (LYB) Poised on Expansion Amid Challenges
Mar-09-17 12:46PM  LYONDELLBASELL INDUSTRIES N.V. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
Mar-07-17 11:35AM  LyondellBasells Interest Expenses Set to Fall Further
10:05AM  What LyondellBasells Debt-to-Equity Ratio Indicates
08:20AM  LyondellBasell Issued $1 Billion of Guaranteed Notes
Feb-28-17 01:06PM  LyondellBasell Prices $1 Billion in Public Offering Guaranteed Notes
Feb-27-17 09:07AM  Why DuPont Is Trading at a Premium Compared to Its Peers
Feb-23-17 05:26PM  LYONDELLBASELL INDUSTRIES N.V. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:04PM  LYONDELLBASELL INDUSTRIES N.V. Financials
Feb-21-17 05:51PM  LyondellBasell Prices Public Offering of Guaranteed Notes PR Newswire
10:33AM  LYB International Finance II B.V. -- Moody's rates LyondellBasell's new notes Baa1, outlook stable at Moody's
Feb-17-17 01:05PM  LYONDELLBASELL INDUSTRIES N.V. Files SEC form 10-K, Annual Report
06:45AM  LyondellBasell Board Authorizes Interim Dividend PR Newswire
Feb-14-17 08:15AM  Post Earnings Coverage as LyondellBasell's Q4 Top-line Beat Market Estimates Accesswire
Feb-08-17 09:06AM  How Are Analysts Viewing LyondellBasell after 4Q16 Earnings?
07:36AM  Why LyondellBasells Refining Segment Revenues Rose in 4Q16
Feb-07-17 02:19PM  LyondellBasell Industries NV :LYB-US: Earnings Analysis: 2016 By the Numbers : February 7, 2017
10:40AM  Why Did LYBs Intermediates and Derivatives Segments Revenue Rise?
09:07AM  How Did LYBs EAI Olefins and Polyolefins Segment Perform in 4Q16?
07:36AM  How Did LYBs Olefins and Polyolefins Americas Segment Fare?
Feb-06-17 05:35PM  LyondellBasells 4Q16 Adjusted Earnings Beat Estimates
03:47PM  LyondellBasell Stock Rose after 4Q16 Revenue Beat Estimates
10:59AM  LyondellBasell Industries NV :LYB-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017
Feb-03-17 04:40PM  Edited Transcript of LYB earnings conference call or presentation 3-Feb-17 4:00pm GMT
02:56PM  LyondellBasell's (LYB) Q4 Earnings, Revenues Top Estimates
08:39AM  LyondellBasell (LYB) Q4 Earnings, Sales Beat Estimates
07:16AM  LyondellBasell tops Street 4Q forecasts
07:07AM  Q4 2016 LyondellBasell Industries NV Earnings Release - Before Market Open
06:45AM  LyondellBasell Reports 2016 Earnings PR Newswire
Feb-02-17 08:34AM  Should You Sell LyondellBasell Industries (LYB) Before Earnings?
06:59AM  FMC Corp (FMC) Q4 Earnings: What's in Store for the Stock?
Feb-01-17 01:30PM  Here's How Valero's Management Thinks Trump's Policies Will Impact the Business at Motley Fool
08:50AM  LyondellBasell (LYB) Q4 Earnings: What's in the Cards?
Jan-30-17 09:30AM  Zacks.com featured highlights: OraSure Technologies, Union Pacific, LyondellBasell Industries, Advanced Energy Industries and Rollins
Jan-27-17 08:32AM  5 Efficient Stocks Potent Enough to Boost Your Returns
Jan-26-17 09:30AM  Zacks Investment Ideas feature highlights: Abb, Applied Materials, Broadcom, LyondellBassel and Union Pacific
09:06AM  Why LyondellBasell Is Trading at a Discount Compared to Peers
07:37AM  Why Most Analysts Recommend a Hold for LyondellBasell
Jan-25-17 02:05PM  Why Analysts Expect 21% Rise in LyondellBasells EPS
12:36PM  Why Analysts Expect LyondellBasells Revenue to Rise in 4Q16
10:58AM  Why LyondellBasell Stock Bounced Back after Disappointing 3Q16
Jan-23-17 02:46PM  8 Stocks Trading Below Peter Lynch Value
01:19PM  LyondellBasell Industries NV : LYB-US: Dividend Analysis : November 29th, 2016 (record date) : By the numbers : January 23, 2017
09:45AM  Is LyondellBasell Industries a Great Stock for Value Investors?
09:06AM  Dow Chemicals Latest Valuations ahead of Its 4Q16 Earnings
09:06AM  A Quick Look at DuPonts Valuation ahead of Its 4Q16 Earnings
Jan-20-17 05:37PM  LyondellBasell to Discuss Fourth-Quarter Results on Friday, February 3, 2017 PR Newswire
03:36PM  7 Price and Earnings Momentum Winners
10:26AM  Will Material ETFs Sustain Their Rally as Q4 Earnings Unfold?
06:57AM  LyondellBasell Wraps Up Corpus Christi Ethylene Expansion
Jan-19-17 10:02AM  Top Ranked Growth Stocks to Buy for January 19th
09:30AM  The Zacks Analyst Blog Highlights: Kronos Worldwide, Ingevity, LyondellBasell Industries NV, Celanese Corporation and Albemarle
06:45AM  LyondellBasell Corpus Christi Complex Expansion Complete PR Newswire
Jan-18-17 05:27PM  LYONDELLBASELL INDUSTRIES N.V. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
05:00PM  LyondellBasell announces planned leadership changes PR Newswire
03:29PM  5 Chemical Growth Stocks to Enrich Your Portfolio in 2017
Jan-13-17 04:06PM  LyondellBasell Donation to Provide Specialized Training for Six Houston-Area Fire Departments PR Newswire
09:11AM  Has DuPonts Stock Performance Retreated?
Jan-10-17 12:10PM  10 Best Stocks for Retired Investors at Kiplinger
08:15AM  Post Earnings Coverage as RPM Sales Up 3%, Earnings Dropped 5.5% Accesswire
Jan-09-17 07:36AM  How Is Dow Chemical Valued Compared to Its Peers?
Jan-06-17 09:07AM  Dow Chemical Stock: The Rapid Surge in December
Jan-05-17 03:50PM  LyondellBasell to keep Houston refinery at bizjournals.com
Jan-04-17 04:36PM  Solvay Has High Ebitda Margins and Is Paying Down Debt
LyondellBasell Industries N.V. operates as a manufacturer of chemicals and polymers, refiner of crude oil, producer of gasoline blending components, and developer and licensor of technologies for production of polymers worldwide. The company operates in five segments: Olefins and PolyolefinsAmericas; Olefins and PolyolefinsEurope, Asia, International; Intermediates and Derivatives; Refining; and Technology. It produces and markets olefins, including ethylene, propylene, and butadiene; polyethylene products, which consist of high density polyethylene, low density polyethylene, and linear low density polyethylene; polyolefins, such as polyethylene and polypropylene (PP); and PP homopolymers, copolymers, and compounds. The company also produces and sells propylene oxide and its derivatives; oxyfuels and related products; and intermediate chemicals, such as styrene monomers, methanol products, glacial acetic acids, vinyl acetate monomers, and ethylene oxides and derivatives. In addition, it refines crude oil into gasoline, diesel, and jet fuel; develops and licenses chemical and polyolefin process technologies; and manufactures and sells polyolefin catalysts, as well as purchases and sells ethylene. The company also exports its products. LyondellBasell Industries N.V. was founded in 2005 and is based in London, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AI New Holdings 2 LLC10% OwnerMar 09Sale89.12139,61712,441,96972,772Mar 10 04:12 PM
AI New Holdings 2 LLC10% OwnerMar 02Sale93.5039,4253,686,23872,912Mar 03 04:48 PM
AI New Holdings 2 LLC10% OwnerMar 01Sale94.32206,78719,504,43972,951Mar 03 04:48 PM
Wolf Jacquelyn HSVP, Human ResourcesFeb 22Option Exercise78.2714,7691,155,95931,283Feb 22 08:13 PM
Wolf Jacquelyn HSVP, Human ResourcesFeb 22Sale94.0114,7691,388,41616,514Feb 22 08:13 PM
AI New Holdings 2 LLC10% OwnerFeb 22Sale94.5514,1711,339,85873,157Feb 24 04:04 PM
AI New Holdings 2 LLC10% OwnerFeb 13Sale92.24862,20579,532,80773,171Feb 14 05:51 PM
AI New Holdings 2 LLC10% OwnerFeb 10Sale92.45305,70028,261,84374,030Feb 14 05:51 PM
AI New Holdings 2 LLC10% OwnerFeb 09Sale92.29900,00083,056,95074,334Feb 09 06:11 PM
AI New Holdings 2 LLC10% OwnerFeb 08Sale91.591,132,095103,689,48775,231Feb 09 06:11 PM
AI New Holdings 2 LLC10% OwnerFeb 07Sale93.021,000,00093,018,14776,359Feb 09 06:11 PM
Bindra Jagjeet S.DirectorAug 30Sale80.013,750300,0208,876Sep 01 09:17 AM
Covezzi MassimoSVP Research & DevelopmentApr 26Sale89.147,551673,1119,702Apr 26 04:28 PM
Vasnetsov SergeySVP Strategic PlanningApr 26Sale89.893,127281,0764,733Apr 26 04:28 PM
TMO Thermo Fisher Scientific Inc. daily Stock Chart
TMO [NYSE]
Thermo Fisher Scientific Inc.
IndexS&P 500 P/E30.86 EPS (ttm)5.10 Insider Own0.20% Shs Outstand394.80M Perf Week2.37%
Market Cap62.12B Forward P/E15.55 EPS next Y10.12 Insider Trans-6.67% Shs Float390.72M Perf Month1.74%
Income2.03B PEG2.91 EPS next Q2.02 Inst Own89.90% Short Float0.96% Perf Quarter10.29%
Sales18.27B P/S3.40 EPS this Y3.50% Inst Trans-0.01% Short Ratio2.25 Perf Half Y3.95%
Book/sh54.56 P/B2.88 EPS next Y10.40% ROA4.50% Target Price173.38 Perf Year7.57%
Cash/sh2.03 P/C77.45 EPS next 5Y10.60% ROE9.50% 52W Range138.80 - 161.66 Perf YTD11.61%
Dividend0.60 P/FCF25.11 EPS past 5Y13.90% ROI6.40% 52W High-2.67% Beta1.10
Dividend %0.38% Quick Ratio1.00 Sales past 5Y9.60% Gross Margin45.80% 52W Low13.36% ATR1.90
Employees55000 Current Ratio1.40 Sales Q/Q6.50% Oper. Margin13.40% RSI (14)61.79 Volatility1.07% 1.06%
OptionableYes Debt/Eq0.77 EPS Q/Q5.90% Profit Margin11.10% Rel Volume0.72 Prev Close155.04
ShortableYes LT Debt/Eq0.71 EarningsApr 26 BMO Payout11.70% Avg Volume1.67M Price157.34
Recom1.70 SMA202.38% SMA500.80% SMA2003.92% Volume1,198,329 Change1.48%
Jan-18-17Initiated Deutsche Bank Buy $163
Nov-10-16Resumed Leerink Partners Outperform
Sep-22-16Resumed JP Morgan Overweight $180
Sep-09-16Downgrade Cleveland Research Buy → Neutral
May-27-16Reiterated Mizuho Buy $166 → $170
May-19-16Reiterated Mizuho Buy $163 → $166
May-03-16Reiterated Mizuho Buy $160 → $163
Apr-29-16Downgrade Jefferies Buy → Hold
Apr-04-16Reiterated Mizuho Buy $150 → $160
Mar-02-16Reiterated Topeka Capital Markets Buy $145 → $155
Jan-11-16Reiterated Stifel Buy $150 → $158
Jan-07-16Initiated Deutsche Bank Buy $160
Oct-06-15Initiated Argus Buy $145
Jul-23-15Reiterated Mizuho Buy $150 → $160
May-21-15Reiterated Barclays Overweight $160 → $165
Mar-10-15Initiated UBS Buy $160
Jan-21-15Reiterated Robert W. Baird Outperform $142 → $144
Aug-12-14Initiated Stifel Buy $150
Jan-30-14Reiterated Mizuho Buy $130 → $140
Jan-30-14Reiterated ISI Group Buy $121.50 → $130
Apr-21-17 07:05AM  Thermo Fisher (TMO) Up 4.5% Since Earnings Report: Can It Continue? Zacks
Apr-20-17 04:20PM  The Top Gene-Sequencing Stock to Buy in 2017 Motley Fool
10:01AM  Will Thermo Fisher (TMO) Pull a Surprise in Q1 Earnings? Zacks
Apr-18-17 06:00AM  New X-ray Machine Handles Heavy Products in Washdown Environments PR Newswire
Apr-05-17 05:35PM  ETFs with exposure to Thermo Fisher Scientific, Inc. : April 5, 2017 Capital Cube
11:18AM  Thermo Fisher Scientific, Inc. : TMO-US: Dividend Analysis : March 15th, 2017 (record date) : By the numbers : April 5, 2017 Capital Cube
Apr-04-17 02:48PM  Thermo Fisher CEO got $59M in compensation, stock value in 2016 American City Business Journals
Mar-31-17 08:30AM  Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 26, 2017 Business Wire
Mar-30-17 08:27AM  Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bearish Manner : TMO-US : March 30, 2017 Capital Cube
Mar-24-17 07:00AM  Exxon, Thermo Fisher and 2 More Are Showing Red Flags TheStreet.com
Mar-23-17 09:38AM  Should Value Investors Consider Thermo Fisher (TMO) Stock? Zacks
Mar-22-17 05:56PM  MedTech Long-Term Prospects Impress: Which Stocks to Buy? Zacks
04:50PM  [$$] GTCR Sells Cole-Parmer Instrument to Golden Gate The Wall Street Journal
Mar-17-17 04:05PM  Thermo Fisher Poised on Innovation, Global Growth Amid Woes Zacks
Mar-16-17 11:37AM  Thermo Fisher Scientific, Inc. :TMO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
06:58AM  THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements an
Mar-10-17 01:40PM  Thermo Fisher Scientific, Inc. :TMO-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017
Mar-08-17 04:45PM  THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-07-17 05:05PM  Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes Business Wire
08:00AM  Thermo Fisher Scientific to Present at the Barclays Global Healthcare Conference on March 14, 2017 Business Wire
07:44AM  Corporates launch funding frenzy in busiest day of year Reuters
Mar-06-17 09:00AM  Thermo Fisher Scientific Showcases Integrated Analytical Workflows During Pittcon 2017 Business Wire
08:48AM  Thermo Fisher Scientific Looks to Enhance Informatics Solutions with Acquisition
Mar-04-17 01:04PM  THERMO FISHER SCIENTIFIC INC. Financials
Mar-02-17 09:26AM  THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to Articles o
Mar-01-17 09:00AM  Thermo Fisher Scientific Elects New Director to Board Business Wire
Feb-28-17 06:46PM  THERMO FISHER SCIENTIFIC INC. Files SEC form 10-K, Annual Report
04:15PM  Thermo Fisher Scientific Declares Quarterly Dividend Business Wire
Feb-26-17 09:25PM  Two Mass. companies involved in some of the biggest tech M&A deals of 2016 at bizjournals.com
Feb-24-17 09:11AM  Patent Damages In The Global Supply Chain at Forbes
Feb-22-17 01:10PM  Thermo Fisher unit prevails in Supreme Court patent case at bizjournals.com
10:25AM  Thermo Fisher Comes Out on Top in Promega Patent Case
10:13AM  Thermo Fisher did not infringe genetic-testing patent, U.S. top court says Reuters
10:11AM  Thermo Fisher Backed by Supreme Court in Promega Patent Case
10:11AM  Patent Royalties Curbed as Supreme Court Backs Thermo Fisher
Feb-14-17 06:15PM  Thermo Fisher Scientific Completes Acquisition of Finesse Solutions, Inc. Business Wire
Feb-13-17 09:15AM  Thermo Fisher Scientific Receives Early Termination of Hart-Scott-Rodino Waiting Period for Acquisition of Finesse Solutions, Inc. Business Wire
Feb-08-17 04:53PM  Better Buy: Illumina, Inc. vs. Thermo Fisher Scientific at Motley Fool
Feb-07-17 08:57AM  Weitz Investment Looks to Visa (V), Amazon (AMZN), Others for Big Returns After Subpar 2016 at Insider Monkey
Feb-02-17 03:10PM  Why the state's two biggest medical device firms have gained $4.5B in market cap this week at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Johnson & Johnson, PayPal, Thermo Fisher, Celgene and American Airlines
Feb-01-17 05:59PM  Final Trade: DIS, GOOGL & more
03:17PM  Top Research Reports for February 1, 2017
Jan-31-17 06:30PM  Why Momenta Pharmaceuticals, Ally Financial, and Thermo Fisher Scientific Jumped Today at Motley Fool +6.35%
04:55PM  The Hot Stock: Thermo Fisher Scientific Jumps 6.4% at Barrons.com
04:37PM  Edited Transcript of TMO earnings conference call or presentation 31-Jan-17 1:30pm GMT
03:19PM  Thermo Fisher Scientific, Inc. : TMO-US: Dividend Analysis : December 15th, 2016 (record date) : By the numbers : January 31, 2017
02:19PM  Thermo Fisher CEO Says M&A Funnel Is 'Pretty Full'
08:58AM  Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
07:42AM  Thermo Fisher (TMO): Tops Q4 Earnings, Misses Revenues
07:07AM  Q4 2016 Thermo Fisher Scientific Inc Earnings Release - Before Market Open
06:26AM  Thermo Fisher beats 4Q profit forecasts
06:02AM  Thermo Fisher quarterly profit tops Wall Street expectations
06:00AM  Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2016 Results Business Wire
Jan-30-17 07:25AM  Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bullish Manner : TMO-US : January 30, 2017
07:06AM  Medical Products Stocks' Earnings on Jan 31: ZBH, TMO, ABC
Jan-26-17 03:17PM  Weitz Funds Comments on Thermo Fisher Scientific
Jan-20-17 04:56PM  John Rogers Comments on Thermo Fisher Scientific Inc.
06:05AM  How a Thermo Fisher employee spurred Mass. biotechs to fight homelessness at bizjournals.com
Jan-19-17 08:34AM  Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bearish Manner : TMO-US : January 19, 2017
Jan-18-17 03:54PM  Coverage initiated on Thermo Fisher by Deutsche Bank
07:40AM  Will Thermo Fisher (TMO) Beat Earnings Estimates in Q4?
Jan-13-17 04:02PM  Santoli: Market's been hard to rattle, but also hard to i...
10:38AM  Behind Johnson & Johnsons Recent Stock Performance
Jan-12-17 05:10PM  Trumps HHS nominee has promised to divest from these Mass. companies at bizjournals.com
Jan-06-17 11:05AM  Thermo Fisher Scientific, Inc. Value Analysis (NYSE:TMO) : January 6, 2017
09:00AM  Thermo Fisher Scientific to Hold Earnings Conference Call on Tuesday, January 31, 2017 Business Wire
Jan-05-17 08:24AM  Thermo Fisher Scientific, Inc. breached its 50 day moving average in a Bullish Manner : TMO-US : January 5, 2017
Jan-04-17 06:05PM  Roberts recuses from patent case after discovering conflict
05:49PM  U.S. chief justice steps aside in patent case over stock conflict Reuters
Jan-03-17 08:30AM  Thermo Fisher Scientific to Present at 35th Annual J.P. Morgan Healthcare Conference on January 10, 2017 Business Wire
Jan-02-17 10:37AM  BD Lifesciencess Product Pipeline Could Boost Its Fiscal 2017 Growth
09:07AM  BD Lifesciencess Performance and Core Focus Areas
Dec-16-16 12:56PM  Billionaire Larry Robbins Knows How To Pick Mega-Cap Stocks at Insider Monkey
Dec-14-16 04:08PM  THERMO FISHER SCIENTIFIC INC. Files SEC form 8-K, Change in Directors or Principal Officers
11:08AM  Illumina Stock Now Worth a Lot Less? Here's What You Need to Know at Motley Fool
Dec-13-16 09:30AM  Zacks.com featured highlights: Arch Capital Group, NICE, First American Financial, Silicon Motion Technology and Thermo Fisher Scientific
Dec-12-16 07:23AM  5 GARP Stocks that Should Grace Your Portfolio
Dec-07-16 11:18AM  A Quick Review of Thermo Fisher
Dec-06-16 04:35PM  Cryder Capital Boosts Bets On Alphabet (GOOG), Credit Cards, Health Stocks at Insider Monkey
07:20AM  Supreme Court case involving Thermo Fisher could affect big manufacturers at bizjournals.com
Dec-03-16 07:43PM  5 Capital Goods Stocks Hedge Funds Were Dumping in Q3 at Insider Monkey
Dec-02-16 02:46PM  MedTech Sails Through Macro Woes: Stocks in Focus
08:05AM  Boston Scientific Completes Its Acquisition of EndoChoice
Dec-01-16 10:05AM  Baxter Makes Significant Advancements in Hemodialysis Treatments
08:05AM  How Baxter Continues to Contribute to Patient Care
Nov-30-16 05:02PM  A Growth Stock in the Land of Value Stocks?
10:48AM  What Are Analysts Recommendations for Thermo Fisher Scientific?
10:48AM  TMO Creates Shareholder Value through Strong Capital Allocation
10:48AM  How Is Thermo Fisher Scientifics FEI Integration Process Going?
10:48AM  How Is Thermo Fisher Scientific Accelerating Growth?
10:48AM  How Has Thermo Fisher Scientifics Stock Performed Recently?
Nov-28-16 02:57PM  Battle of Bulls and Bears Lies Ahead for Thermo Fisher
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems to support clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; and human leukocyte antigen typing and testing for organ transplant market. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers controlled temperature technology products; sample preparation and preservation equipment; centrifugation products and biological safety cabinets; water analysis instruments and laboratory equipment; laboratory consumables; chemicals; and research and safety market channel, and biopharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILVER PETER MExec. VP & Chief Admin OfficerMar 15Sale160.739,0791,459,26862,517Mar 16 05:11 PM
CASPER MARC NChief Executive OfficerMar 15Sale158.6020,0003,172,000289,279Mar 16 05:07 PM
WILVER PETER MExec. VP & Chief Admin OfficerMar 10Option Exercise126.229,9871,260,56081,583Mar 13 05:14 PM
WILVER PETER MExec. VP & Chief Admin OfficerMar 10Sale158.189,9871,579,74471,596Mar 13 05:14 PM
Loewald Thomas WSenior Vice PresidentMar 08Option Exercise73.247,675562,11750,484Mar 09 04:13 PM
Loewald Thomas WSenior Vice PresidentMar 08Sale157.397,6751,207,96842,809Mar 09 04:13 PM
Williamson StephenSr. VP and CFOMar 06Sale158.712,500396,77540,290Mar 08 05:15 PM
Loewald Thomas WSenior Vice PresidentMar 06Sale158.714,049642,61742,809Mar 08 05:12 PM
HOOGASIAN SETH HSr. VP and Gen. CounselMar 06Sale158.713,142498,66731,104Mar 08 05:10 PM
CASPER MARC NChief Executive OfficerSep 02Option Exercise54.9728,7971,582,971307,444Sep 06 04:52 PM
CASPER MARC NChief Executive OfficerSep 02Sale151.0128,7974,348,635278,647Sep 06 04:52 PM
CASPER MARC NChief Executive OfficerSep 01Option Exercise54.9730,0001,649,100308,647Sep 02 05:32 PM
CASPER MARC NChief Executive OfficerSep 01Sale151.1730,0004,535,076278,647Sep 02 05:32 PM
Shine Daniel PSenior Vice PresidentAug 29Sale152.281,699258,72417,437Aug 31 05:00 PM
Loewald Thomas WSenior Vice PresidentAug 29Sale152.283,256495,82435,814Aug 31 04:58 PM
HOOGASIAN SETH HSr. VP, Gen. Counsel & Sec.Aug 29Sale152.282,270345,67627,384Aug 31 04:56 PM
Shine Daniel PSenior Vice PresidentAug 26Sale151.7847672,24719,136Aug 30 05:20 PM
Loewald Thomas WSenior Vice PresidentAug 26Sale151.92913138,70339,070Aug 30 05:17 PM
CASPER MARC NChief Executive OfficerAug 15Sale155.9625,0003,899,031295,998Aug 17 04:54 PM
HOOGASIAN SETH HSr. VP, Gen. Counsel & Sec.Aug 10Sale156.005,023783,58831,914Aug 11 04:46 PM
HARRIS C MARTINDirectorAug 05Sale157.3339061,3594,648Aug 08 04:53 PM
Loewald Thomas WSenior Vice PresidentJul 13Option Exercise73.248,025587,75152,194Jul 14 04:35 PM
Loewald Thomas WSenior Vice PresidentJul 13Sale155.008,0251,243,87544,169Jul 14 04:35 PM
CASPER MARC NChief Executive OfficerJul 05Option Exercise54.9720,0001,099,400340,998Jul 07 04:42 PM
CASPER MARC NChief Executive OfficerJul 05Sale147.6920,0002,953,804320,998Jul 07 04:42 PM
CASPER MARC NChief Executive OfficerJul 01Option Exercise54.9730,0001,649,100350,998Jul 06 04:42 PM
CASPER MARC NChief Executive OfficerJul 01Sale148.8530,0004,465,638320,998Jul 06 04:42 PM
Shine Daniel PSenior Vice PresidentJun 15Option Exercise54.976,900379,29328,779Jun 16 05:00 PM
Shine Daniel PSenior Vice PresidentJun 15Sale148.316,9001,023,35621,879Jun 16 05:00 PM
WILVER PETER MExec. VP & Chief Admin OfficerJun 10Option Exercise54.9768,2003,748,954138,777Jun 14 04:47 PM
WILVER PETER MExec. VP & Chief Admin OfficerJun 10Sale152.3868,20010,392,63370,577Jun 14 04:47 PM
MANZI JIM PDirectorJun 03Sale153.001,137173,96138,733Jun 06 04:41 PM
Loewald Thomas WSenior Vice PresidentJun 02Option Exercise73.2415,0001,098,60059,169Jun 06 04:39 PM
Loewald Thomas WSenior Vice PresidentJun 02Sale152.8415,0002,292,60044,169Jun 06 04:39 PM
Williamson StephenSr. VP and CFOMay 25Option Exercise54.973,740205,58833,821May 26 04:38 PM
Williamson StephenSr. VP and CFOMay 24Option Exercise54.978,660476,04038,741May 26 04:38 PM
Williamson StephenSr. VP and CFOMay 24Sale150.298,6601,301,48330,081May 26 04:38 PM
HORNSTRA PETER EVP & Chief Accounting OfficerMay 16Option Exercise68.386,357434,69425,671May 17 11:39 AM
HORNSTRA PETER EVP & Chief Accounting OfficerMay 16Sale150.007,8111,171,65017,860May 17 11:39 AM
Shine Daniel PSenior Vice PresidentApr 26Option Exercise54.975,000274,85027,892Apr 27 04:09 PM
Shine Daniel PSenior Vice PresidentApr 26Sale146.006,013877,89821,879Apr 27 04:09 PM
CRM Salesforce.com, inc. daily Stock Chart
CRM [NYSE]
Salesforce.com, inc.
IndexS&P 500 P/E324.98 EPS (ttm)0.26 Insider Own0.10% Shs Outstand702.87M Perf Week-0.04%
Market Cap59.16B Forward P/E50.19 EPS next Y1.68 Insider Trans-76.64% Shs Float670.60M Perf Month3.25%
Income179.60M PEG11.63 EPS next Q0.26 Inst Own86.10% Short Float2.18% Perf Quarter10.52%
Sales8.39B P/S7.05 EPS this Y457.90% Inst Trans0.11% Short Ratio3.27 Perf Half Y15.95%
Book/sh10.68 P/B7.88 EPS next Y30.20% ROA1.20% Target Price96.00 Perf Year10.05%
Cash/sh3.14 P/C26.78 EPS next 5Y27.94% ROE2.80% 52W Range66.43 - 86.42 Perf YTD22.95%
Dividend- P/FCF34.84 EPS past 5Y69.50% ROI2.10% 52W High-2.60% Beta1.28
Dividend %- Quick Ratio0.80 Sales past 5Y29.90% Gross Margin73.40% 52W Low26.70% ATR1.02
Employees25000 Current Ratio0.80 Sales Q/Q26.80% Oper. Margin0.70% RSI (14)56.96 Volatility1.02% 1.26%
OptionableYes Debt/Eq0.36 EPS Q/Q-92.20% Profit Margin2.10% Rel Volume0.71 Prev Close83.79
ShortableYes LT Debt/Eq0.36 EarningsMay 30 AMC Payout0.00% Avg Volume4.48M Price84.17
Recom1.80 SMA201.01% SMA501.79% SMA2008.93% Volume3,193,843 Change0.45%
Mar-01-17Reiterated Wedbush Outperform $98 → $102
Feb-28-17Resumed Robert W. Baird Outperform $90
Feb-16-17Initiated Needham Hold
Jan-12-17Downgrade Pivotal Research Group Buy → Hold $105 → $76
Jan-11-17Initiated Wells Fargo Outperform
Nov-18-16Reiterated Wedbush Outperform $96 → $98
Nov-18-16Reiterated Mizuho Buy $85 → $95
Nov-18-16Reiterated BMO Capital Markets Outperform $86 → $90
Oct-18-16Initiated Rosenblatt Buy $90
Sep-01-16Reiterated Wedbush Outperform $98 → $96
Sep-01-16Reiterated RBC Capital Mkts Outperform $91 → $85
Sep-01-16Reiterated Mizuho Buy $100 → $85
Sep-01-16Reiterated BMO Capital Markets Outperform $98 → $86
Jun-15-16Initiated BMO Capital Markets Outperform $98
May-19-16Reiterated Wunderlich Buy $93 → $101
May-19-16Reiterated Wedbush Outperform $95 → $98
May-19-16Reiterated Stifel Buy $85 → $93
May-19-16Reiterated MKM Partners Buy $86 → $96
May-19-16Reiterated Mizuho Buy $90 → $100
May-19-16Reiterated Canaccord Genuity Buy $88 → $95
Apr-24-17 08:43PM  QuintilesIMS in Deal to Use Salesforce.coms Cloud Technology The Wall Street Journal
06:05PM  Customer Relationship Management: Could Salesforce Lose Its Lead? Market Realist
04:57PM  Microsoft Announces First Official LinkedIn Integrations Motley Fool
04:42PM  CEO Gassner Makes Sure Veeva Has A 'Second Act' And More Investor's Business Daily
04:41PM  Microsoft Is Helping LinkedIn Realize Its Untapped Potential TheStreet.com
04:36PM  Why Salesforces Focus on Japan Is Opportune Market Realist
03:43PM  Microsoft's Nadella banks on LinkedIn data to challenge Salesforce Reuters
02:59PM  Salesforces Data Center Expansion in Japan: A Strategic Move? Market Realist
05:30AM  QuintilesIMS in Deal to Use Salesforce.com's Cloud Technology The Wall Street Journal
Apr-22-17 10:15AM  Oracle's Latest Acquisition Shows the Ad Software Arms Race Remains in Full Swing TheStreet.com
Apr-19-17 11:20AM  Values and feedback drive culture at Salesforce, with a suite of high-end perks American City Business Journals
Apr-18-17 03:12PM  Your Chance At The Next Facebook Forbes
Apr-17-17 12:52PM  Salesforce CEO Marc Benioff sure is happy about his big new tower Business Insider
09:39AM  Salesforce (CRM) Bets Big on Japan, Opens 2nd Data Center Zacks
Apr-14-17 09:22PM  Okta, Inc. IPO: What Investors Need to Know Motley Fool
Apr-13-17 10:00PM  Salesforce Opens Second Data Center in Japan to Deliver the Salesforce Intelligent Customer Success Platform to Customers Locally PR Newswire
08:00AM  Salesforce Achieves Net-Zero Greenhouse Gas Emissions PR Newswire
Apr-11-17 09:02AM  Veeva Systems Inc: Buy at the High? Motley Fool
Apr-09-17 03:36PM  Top Insider Buys Highlight for the Week of April 7 GuruFocus.com
Apr-08-17 12:02AM  [$$] Evercore ISI Sees 20% Upside in Salesforce.com Barrons.com
Apr-07-17 04:49PM  Okta Surges in Stock Debut, but Investors Should Be Wary of Microsoft TheStreet.com
02:24PM  What San Francisco looks like from city's tallest building, Salesforce Tower American City Business Journals
12:39PM  Stay Cautious With Salesforce for These Reasons GuruFocus.com
09:51AM  Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks Investor's Business Daily
Apr-06-17 12:53PM  Salesforce and Community Leaders Gather to Celebrate "Topping Off" of Salesforce Tower San Francisco PR Newswire
Apr-05-17 06:57PM  Two outgoing CEOs added to Cramer's Wall of Fame CNBC Videos
06:52PM  Cramer taps two highly successful outgoing CEOs for his W... CNBC Videos
03:52PM  Options Action Suggests CRM Is Breaking Out Investopedia
02:42PM  Salesforce Refuses to Stop Surging to Record Highs TheStreet.com
02:30PM  Here's Why Salesforce.com (CRM) Stock Popped Today Zacks
08:35AM  Merrill Lynch Makes Huge Tech Stock Addition to US 1 Portfolio 24/7 Wall St.
Apr-04-17 04:50PM  Project Alpha Intermediate Holding, Inc. -- Moody's assigns B3 CFR to Qlik Technologies, B3 ratings to new revolver and term loan; outlook stable Moody's
01:35PM  Day's biggest movers: Staples, Exxon, Amazon and more CNBC Videos
08:00AM  Salesforce Introduces Einstein High Velocity Sales Cloud - The Next Generation of Sales Powered by AI PR Newswire
07:55AM  City and County of Denver Implements Salesforce 311 Solution to Connect With Citizens in Smarter, More Modern Ways
07:50AM  Salesforce Government Cloud Granted Department of Defense Impact Level 4 Provisional Authorization, Enabling Additional Government Agencies to Benefit from the Cloud
Apr-03-17 08:00AM  Patricia Arquette, Mary J. Blige, Billie Jean King and Lilly Ledbetter to be Honored at Inaugural Salesforce Equality Awards Event PR Newswire
Apr-02-17 11:12AM  3 Top Artificial Intelligence Stocks to Buy in 2017 at Motley Fool
Mar-31-17 04:15PM  Salesforce to Feature the World's Most Innovative Thought Leaders in Equal Pay, Artificial Intelligence and Workforce Development at World Tour Event in Washington D.C. PR Newswire
03:23PM  Forget Snap, Here's a Look at the Most Eye-Popping IPOs of 2017
07:30AM  Salesforce Executive to Participate in Upcoming Investor Event PR Newswire
Mar-30-17 05:18AM  This Market Loves Tech: Cramer's 'Mad Money' Recap (Wednesday 3/29/17)
Mar-29-17 11:23AM  IBM's Solutions Drive Bulgaria-based Praktiker's Sales
11:20AM  Analysts Shoot Down Oracle-Accenture Deal; 'Why Buy The Cow?'
10:03AM  Will Cisco Separately Sell Network Operating Software Lindt? at Investopedia
08:00AM  Salesforce Mobile App Development Platform Named a Leader by Independent Research Firm PR Newswire
Mar-28-17 02:38PM  Salesforce's chief diplomat on what it's like being BFFs with Amazon's $12 billion cloud
02:29PM  Salesforce.com: Go Long, but Only on Strength
01:00PM  Investing in Veeva Systems Upside with Options MrTopStep.com
09:16AM  Salesforce Announces Service Cloud Einstein and Amazon Connect Integration PR Newswire
08:01AM  Salesforce Launches Financial Services Cloud Einstein -- AI-Powered CRM for Financial Advisors PR Newswire
08:00AM  Transamerica Chooses Salesforce Financial Services Cloud Einstein for its 'Customer First' Digital Transformation PR Newswire
Mar-27-17 03:53PM  ETFs with exposure to salesforce.com, inc. : March 27, 2017
03:39PM  Jared Kushner's 'innovation' office will get advice from Bill Gates, Tim Cook and Elon Musk
03:00PM  Better Buy: Veeva Systems Inc vs. salesforce.com, inc. at Motley Fool
03:00AM  Cognizant Opens European Customer Success Centre to Accelerate Client Digital Transformations with Salesforce Platform PR Newswire
Mar-26-17 01:01PM  Carrier deal touted by Trump unusual for Indiana AP
Mar-24-17 04:30PM  Salesforce Grants Equity Awards Under Its Inducement Equity Incentive Plan PR Newswire
04:05PM  Salesforce Named a Leader in B2C Commerce Suites by Independent Research Firm PR Newswire
01:41PM  A Look at Oracles Cloud Offerings Business in Fiscal 3Q17
Mar-23-17 05:40PM  How Adobe Can Plug the Holes in Its Cloud at TheStreet
04:15PM  Salesforce Chairman and CEO Marc Benioff to Speak at World Economic Forum Event PR Newswire
12:02PM  How Salesforce's Pending Accounting Changes Could Lead To A Large One-Time Gain
10:33AM  [$$] Salesforce: peering at clouds at Financial Times
07:35AM  What Can Salesforce Achieve in Brazil? at Market Realist
Mar-22-17 07:01PM  Cramer: Current Market Narrative Makes No Sense
09:32AM  salesforce.com, inc. :CRM-US: Earnings Analysis: Q4, 2017 By the Numbers : March 22, 2017
09:05AM  Are These Funds Plotting to Oust Salesforce CEO Marc Benioff? at Market Realist
07:35AM  Salesforce Gives Microsoft Another Reason to Worry at Market Realist
06:11AM  Why Stocks Fall Through No Fault of Their Own: Cramer's 'Mad Money' Recap (Tuesday 3/21/17)
Mar-21-17 03:38PM  IBM CEO Rometty on Growing Cloud Business, U.S. Workforce
02:58PM  Marc Benioff Doesn't See Salesforce Doing a Lot of M&A
02:50PM  Salesforce CEO Marc Benioff on IBM Partnership and M&A
11:12AM  Microsoft is giving Salesforce a real run for its money
10:43AM  Microsoft Collaborates with Adobe to Gain CRM Dominance
09:14AM  Salesforce (CRM) to Host Core Products in Australia with AWS
08:57AM  Why Salesforce and First Solar Are Scrambling To Buy A Piece Of This Multi-Trillion Dollar Market
08:30AM  Why salesforce.com and First Solar Are Scrambling To Buy A Piece Of This Multi-Trillion Dollar Market Accesswire
07:35AM  What Could Boost Oracle Stock in 2017? at Market Realist
07:26AM  Microsoft, Adobe Team Up to Provide Businesses Joint Solutions at Investopedia
Mar-20-17 09:39PM  Salesforce platform to be delivered out of AWS' Australian datacentres at ZDNet
07:00PM  Salesforce to Deliver the Salesforce Intelligent Customer Success Platform to Customers in Australia Using Amazon Web Services Cloud Infrastructure PR Newswire
04:19PM  Marc Benioff Wants Gov't to Create, Fund Apprenticeships
02:23PM  Exclusive: Uber buys stake in Mission Bay Warriors arena office project, but pulls back in Oakland at bizjournals.com
10:44AM  Paycom's Small And Midsize Business Flair Gets It A Price Hike
10:37AM  What Salesforce Is Buying in the Startup Market
09:13AM  Can Veeva Stock Keep Going After Last Week's 10% Pop? at Motley Fool
08:00AM  Salesforce Chairman and CEO Marc Benioff to Speak at IBM InterConnect PR Newswire
Mar-18-17 01:21AM  [$$] Changes at Oracle, IBM, and Intel: Less Than Meets the Eye at Barrons.com
Mar-17-17 10:39PM  Job training session with Merkel shows Ivanka's influence
03:56PM  Is the IBM-Salesforce Partnership about Killing Microsoft?
02:45PM  Adobe Is Digital Growth and A Top Tech Stock
01:58PM  IBM Announces 2,000 New Jobs for Vets in Effort to Woo White House
09:45AM  Salesforce CEO Benioff Headed to Washington Today at TheStreet
08:00AM  [video]Adobe's Earnings Say a Lot About How Cloud Subscriptions Are Growing Its Available Market at TheStreet
06:04AM  SALESFORCE COM INC Files SEC form 8-K, Change in Directors or Principal Officers
Mar-16-17 04:17PM  IBD 50 Company Breaks Out After Deepening Salesforce Tie-Up
04:03PM  Oracle cloud sales trigger buying frenzy at MarketWatch
02:50PM  Is ORCL A Top Tech Stock?
01:19PM  This Algo Is Bullish On Banks And Tech
Salesforce.com, inc. develops enterprise cloud computing solutions with a focus on customer relationship management. The company offers Sales Cloud to store data, monitor leads and progress, forecast opportunities, gain insights through relationship intelligence, and collaborate around sales on desktop and mobile devices, as well as solutions for partner relationship management. It also provides Service Cloud, which enables companies to deliver personalized customer service and support, as well as connects their service agents with customers on various devices; and Marketing Cloud to plan, personalize, and optimize one-to-one customer interactions. In addition, the company offers Commerce Cloud to deliver a digital commerce experience; Community Cloud to create and manage branded digital destinations for customers, partners, and employees; Internet of Things Cloud that provides insights to companies enabling them to sell, service, and market to their customers in personalized ways, as well as engage with them in real time; and Analytics Cloud that enables employees across an organization to explore business data, uncover new insights, make decisions, and take action from various devices. Further, it provides Salesforce Quip, a next-generation productivity solution for teams with a mobile-first strategy to collaborate without email; and Salesforce Platform for building enterprise apps. Additionally, the company offers professional cloud services, such as consulting, deployment, training, user-centric design, and integration to facilitate the adoption of its solutions; and architects and innovation program teams, as well as various education services comprising introductory online courses and advanced architecture certifications. Salesforce.com, inc. offers its services through direct sales; and through consulting firms, systems integrators, and other partners. The company was founded in 1999 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Benioff MarcChairman of the Board and CEOApr 24Option Exercise39.0910,000390,92534,195,300Apr 24 08:00 PM
Benioff MarcChairman of the Board and CEOApr 24Sale84.0710,000840,70734,185,300Apr 24 08:00 PM
Benioff MarcChairman of the Board and CEOApr 21Option Exercise39.0910,000390,92534,195,300Apr 24 08:00 PM
Benioff MarcChairman of the Board and CEOApr 21Sale83.8910,000838,88634,185,300Apr 24 08:00 PM
BLOCK KEITHPres., Vice Chairman and COOApr 20Option Exercise37.9510,000379,50010,000Apr 20 07:13 PM
Benioff MarcChairman of the Board and CEOApr 20Option Exercise39.0910,000390,92534,195,300Apr 20 08:11 PM
Roos John VictorDirectorApr 20Sale83.9919416,29417,423Apr 20 07:09 PM
BLOCK KEITHPres., Vice Chairman and COOApr 20Sale83.6410,000836,3560Apr 20 07:13 PM
Benioff MarcChairman of the Board and CEOApr 20Sale83.9310,000839,26634,185,300Apr 20 08:11 PM
Benioff MarcChairman of the Board and CEOApr 19Option Exercise39.0910,000390,92534,195,300Apr 19 07:55 PM
Benioff MarcChairman of the Board and CEOApr 19Sale83.7810,000837,78334,185,300Apr 19 07:55 PM
BLOCK KEITHPres., Vice Chairman and COOApr 18Option Exercise37.9510,000379,50010,000Apr 18 09:02 PM
Benioff MarcChairman of the Board and CEOApr 18Option Exercise39.0910,000390,92534,195,300Apr 18 09:05 PM
BLOCK KEITHPres., Vice Chairman and COOApr 18Sale84.2110,000842,1000Apr 18 09:02 PM
Benioff MarcChairman of the Board and CEOApr 18Sale83.8810,000838,81734,185,300Apr 18 09:05 PM
Benioff MarcChairman of the Board and CEOApr 17Option Exercise39.0910,000390,92534,195,300Apr 17 09:00 PM
Conway CraigDirectorApr 17Sale83.2525020,8139,352Apr 17 08:50 PM
Benioff MarcChairman of the Board and CEOApr 17Sale83.9210,000839,20634,185,300Apr 17 09:00 PM
BLOCK KEITHPres., Vice Chairman and COOApr 13Option Exercise37.9510,000379,50010,000Apr 13 08:10 PM
Benioff MarcChairman of the Board and CEOApr 13Option Exercise39.0910,000390,92534,195,300Apr 13 09:21 PM
BLOCK KEITHPres., Vice Chairman and COOApr 13Sale83.3410,000833,3640Apr 13 08:10 PM
Roos John VictorDirectorApr 13Sale83.2019416,14117,617Apr 13 09:18 PM
Benioff MarcChairman of the Board and CEOApr 13Sale83.5810,000835,78134,185,300Apr 13 09:21 PM
Benioff MarcChairman of the Board and CEOApr 12Option Exercise39.0910,000390,92534,195,300Apr 13 09:21 PM
Benioff MarcChairman of the Board and CEOApr 12Sale83.5210,000835,19634,185,300Apr 13 09:21 PM
Benioff MarcChairman of the Board and CEOApr 11Option Exercise39.0910,000390,92534,195,300Apr 11 09:02 PM
BLOCK KEITHPres., Vice Chairman and COOApr 11Option Exercise37.9510,000379,50010,000Apr 11 09:06 PM
Benioff MarcChairman of the Board and CEOApr 11Sale83.7010,000836,96334,185,300Apr 11 09:02 PM
BLOCK KEITHPres., Vice Chairman and COOApr 11Sale83.7410,000837,4290Apr 11 09:06 PM
Benioff MarcChairman of the Board and CEOApr 10Option Exercise39.0910,000390,92534,195,300Apr 11 09:02 PM
Benioff MarcChairman of the Board and CEOApr 10Sale84.2610,000842,55634,185,300Apr 11 09:02 PM
Benioff MarcChairman of the Board and CEOApr 07Option Exercise39.0910,000390,92534,195,300Apr 11 09:02 PM
Benioff MarcChairman of the Board and CEOApr 07Sale84.3010,000843,02434,185,300Apr 11 09:02 PM
BLOCK KEITHPres., Vice Chairman and COOApr 06Option Exercise37.9510,000379,50010,000Apr 06 08:42 PM
Benioff MarcChairman of the Board and CEOApr 06Option Exercise39.0910,000390,92534,195,300Apr 06 08:10 PM
BLOCK KEITHPres., Vice Chairman and COOApr 06Sale84.8110,000848,1260Apr 06 08:42 PM
Roos John VictorDirectorApr 06Sale85.3519416,55817,811Apr 06 08:03 PM
Benioff MarcChairman of the Board and CEOApr 06Sale84.8710,000848,74234,185,300Apr 06 08:10 PM
Benioff MarcChairman of the Board and CEOApr 05Option Exercise39.0910,000390,92534,195,300Apr 05 09:19 PM
WEBB MAYNARD G JRDirectorApr 05Sale85.002,345199,32534,063Apr 05 09:13 PM
Benioff MarcChairman of the Board and CEOApr 05Sale85.0010,000849,97234,185,300Apr 05 09:19 PM
Benioff MarcChairman of the Board and CEOApr 04Option Exercise39.0910,000390,92534,195,300Apr 04 07:26 PM
BLOCK KEITHPres., Vice Chairman and COOApr 04Option Exercise37.9510,000379,50010,000Apr 04 07:35 PM
Benioff MarcChairman of the Board and CEOApr 04Sale82.8710,000828,67134,185,300Apr 04 07:26 PM
BLOCK KEITHPres., Vice Chairman and COOApr 04Sale82.8210,000828,1890Apr 04 07:35 PM
Weaver Amy EPres., Legal & General CounselApr 03Option Exercise52.304,137216,36521,863Apr 03 08:50 PM
Benioff MarcChairman of the Board and CEOApr 03Option Exercise39.0910,000390,92534,195,300Apr 03 08:55 PM
Wojcicki SusanDirectorApr 03Buy82.701,20999,98426,763Apr 03 08:42 PM
Weaver Amy EPres., Legal & General CounselApr 03Sale82.614,137341,75817,726Apr 03 08:50 PM
Benioff MarcChairman of the Board and CEOApr 03Sale82.2310,000822,29634,185,300Apr 03 08:55 PM
Benioff MarcChairman of the Board and CEOMar 31Option Exercise39.0910,000390,92534,195,300Apr 03 08:55 PM
Benioff MarcChairman of the Board and CEOMar 31Sale82.6710,000826,68234,185,300Apr 03 08:55 PM
BLOCK KEITHPres., Vice Chairman and COOMar 30Option Exercise37.9510,000379,50010,000Mar 30 09:13 PM
Benioff MarcChairman of the Board and CEOMar 30Option Exercise39.0910,000390,92534,195,300Mar 30 09:18 PM
Robbins Cynthia G.EVP, Global Employee SuccessMar 30Sale82.332,000164,660364Mar 30 09:10 PM
BLOCK KEITHPres., Vice Chairman and COOMar 30Sale82.3310,000823,3190Mar 30 09:13 PM
Benioff MarcChairman of the Board and CEOMar 30Sale82.3210,000823,22434,185,300Mar 30 09:18 PM
Roos John VictorDirectorMar 30Sale82.2519415,95718,005Mar 30 09:23 PM
Benioff MarcChairman of the Board and CEOMar 29Option Exercise39.0910,000390,92534,195,300Mar 30 09:18 PM
Benioff MarcChairman of the Board and CEOMar 29Sale82.1410,000821,40734,185,300Mar 30 09:18 PM
Benioff MarcChairman of the Board and CEOMar 28Option Exercise39.0910,000390,92534,195,300Mar 28 09:49 PM
BLOCK KEITHPres., Vice Chairman and COOMar 28Option Exercise37.9510,000379,50010,000Mar 28 09:57 PM
Benioff MarcChairman of the Board and CEOMar 28Sale81.9510,000819,53334,185,300Mar 28 09:49 PM
BLOCK KEITHPres., Vice Chairman and COOMar 28Sale81.6810,000816,7880Mar 28 09:57 PM
Benioff MarcChairman of the Board and CEOMar 27Option Exercise39.0910,000390,92534,195,300Mar 28 09:49 PM
Hawkins Mark JChief Financial OfficerMar 27Option Exercise59.648,624514,33521,264Mar 28 09:52 PM
Benioff MarcChairman of the Board and CEOMar 27Sale81.4210,000814,15834,185,300Mar 28 09:49 PM
Hawkins Mark JChief Financial OfficerMar 27Sale80.848,624697,17612,640Mar 28 09:52 PM
Benioff MarcChairman of the Board and CEOMar 24Option Exercise39.0910,000390,92534,195,300Mar 24 08:24 PM
Benioff MarcChairman of the Board and CEOMar 24Sale81.7610,000817,56134,185,300Mar 24 08:24 PM
BLOCK KEITHPres., Vice Chairman and COOMar 23Option Exercise37.9510,000379,50010,000Mar 24 08:04 PM
Benioff MarcChairman of the Board and CEOMar 23Option Exercise39.0910,000390,92534,195,300Mar 23 07:25 PM
Norton Burke FEVP and Chief Legal OfficerMar 23Option Exercise39.09210,8008,240,699290,385Mar 23 08:09 PM
BLOCK KEITHPres., Vice Chairman and COOMar 23Sale81.7610,000817,6280Mar 24 08:04 PM
Benioff MarcChairman of the Board and CEOMar 23Sale81.8610,000818,56934,185,300Mar 23 07:25 PM
Norton Burke FEVP and Chief Legal OfficerMar 23Sale81.73210,80017,228,62179,585Mar 23 08:09 PM
Roos John VictorDirectorMar 23Sale82.0019415,90818,199Mar 23 08:12 PM
Benioff MarcChairman of the Board and CEOMar 22Option Exercise39.0910,000390,92534,195,300Mar 22 07:39 PM
Benioff MarcChairman of the Board and CEOMar 22Sale81.6410,000816,44934,185,300Mar 22 07:39 PM
Benioff MarcChairman of the Board and CEOMar 21Option Exercise39.0910,000390,92534,195,300Mar 21 08:00 PM
BLOCK KEITHPres., Vice Chairman and COOMar 21Option Exercise37.9510,000379,50010,000Mar 21 08:50 PM
Benioff MarcChairman of the Board and CEOMar 21Sale82.0810,000820,79734,185,300Mar 21 08:00 PM
BLOCK KEITHPres., Vice Chairman and COOMar 21Sale82.9510,000829,4780Mar 21 08:50 PM
Benioff MarcChairman of the Board and CEOMar 20Option Exercise39.0910,000390,92534,195,300Mar 20 07:51 PM
Benioff MarcChairman of the Board and CEOMar 20Sale83.1910,000831,88734,185,300Mar 20 07:51 PM
Benioff MarcChairman of the Board and CEOMar 17Option Exercise39.0910,000390,92534,195,300Mar 20 07:51 PM
Benioff MarcChairman of the Board and CEOMar 17Sale83.3810,000833,77734,185,300Mar 20 07:51 PM
BLOCK KEITHPres., Vice Chairman and COOMar 16Option Exercise37.9510,000379,50010,000Mar 16 08:15 PM
Benioff MarcChairman of the Board and CEOMar 16Option Exercise39.0910,000390,92534,195,300Mar 16 08:19 PM
Roos John VictorDirectorMar 16Sale83.8819416,27318,393Mar 16 08:00 PM
BLOCK KEITHPres., Vice Chairman and COOMar 16Sale83.6410,000836,4080Mar 16 08:15 PM
Benioff MarcChairman of the Board and CEOMar 16Sale83.5310,000835,26934,185,300Mar 16 08:19 PM
Benioff MarcChairman of the Board and CEOMar 15Option Exercise39.0910,000390,92534,195,300Mar 15 07:41 PM
Benioff MarcChairman of the Board and CEOMar 15Sale83.4310,000834,32334,185,300Mar 15 07:41 PM
Conway CraigDirectorMar 15Sale83.561,10992,6689,602Mar 15 07:59 PM
Benioff MarcChairman of the Board and CEOMar 14Option Exercise39.0910,000390,92534,195,300Mar 14 08:22 PM
BLOCK KEITHPres., Vice Chairman and COOMar 14Option Exercise37.9510,000379,50010,000Mar 14 08:37 PM
Benioff MarcChairman of the Board and CEOMar 14Sale83.1810,000831,76234,185,300Mar 14 08:22 PM
BLOCK KEITHPres., Vice Chairman and COOMar 14Sale83.3510,000833,5490Mar 14 08:37 PM
Benioff MarcChairman of the Board and CEOMar 13Option Exercise39.0910,000390,92534,195,300Mar 13 06:49 PM
AGN Allergan plc daily Stock Chart
AGN [NYSE]
Allergan plc
IndexS&P 500 P/E- EPS (ttm)-3.12 Insider Own0.20% Shs Outstand356.40M Perf Week0.36%
Market Cap84.46B Forward P/E13.23 EPS next Y17.91 Insider Trans-8.22% Shs Float334.81M Perf Month0.72%
Income-1219.50M PEG- EPS next Q3.32 Inst Own93.00% Short Float3.37% Perf Quarter10.63%
Sales14.57B P/S5.80 EPS this Y63.30% Inst Trans0.03% Short Ratio3.81 Perf Half Y1.96%
Book/sh199.95 P/B1.19 EPS next Y11.71% ROA10.90% Target Price268.67 Perf Year3.72%
Cash/sh37.11 P/C6.39 EPS next 5Y13.90% ROE19.60% 52W Range183.98 - 260.53 Perf YTD13.16%
Dividend2.80 P/FCF103.82 EPS past 5Y-28.70% ROI0.10% 52W High-9.04% Beta1.16
Dividend %1.18% Quick Ratio2.20 Sales past 5Y26.00% Gross Margin87.20% 52W Low28.81% ATR2.93
Employees16700 Current Ratio2.30 Sales Q/Q7.10% Oper. Margin-12.50% RSI (14)44.50 Volatility1.10% 1.24%
OptionableYes Debt/Eq0.47 EPS Q/Q85.60% Profit Margin- Rel Volume0.73 Prev Close236.35
ShortableYes LT Debt/Eq0.42 EarningsMay 09 BMO Payout0.00% Avg Volume2.97M Price236.98
Recom2.00 SMA20-0.52% SMA50-1.60% SMA2003.83% Volume2,151,864 Change0.27%
Feb-09-17Reiterated Mizuho Buy $273 → $275
Dec-09-16Reiterated Credit Suisse Outperform $301 → $274
Nov-17-16Reiterated Mizuho Buy $293 → $273
Nov-03-16Reiterated RBC Capital Mkts Outperform $300 → $279
Nov-01-16Reiterated Mizuho Buy $299 → $293
Oct-31-16Resumed Barclays Equal Weight $250
Oct-11-16Reiterated Mizuho Buy $305 → $299
Aug-19-16Upgrade Mizuho Neutral → Buy $248 → $318
Aug-09-16Reiterated RBC Capital Mkts Outperform $307 → $300
Aug-09-16Reiterated Deutsche Bank Buy $282 → $278
Aug-05-16Reiterated Mizuho Neutral $232 → $246
Jul-27-16Reiterated Leerink Partners Outperform $272 → $294
Jul-25-16Initiated Credit Suisse Outperform $327
May-13-16Reiterated Mizuho Neutral $250 → $232
Apr-18-16Resumed Goldman Buy $275
Apr-18-16Initiated Guggenheim Neutral
Apr-18-16Downgrade Piper Jaffray Overweight → Neutral $311 → $238
Apr-07-16Resumed Morgan Stanley Overweight $300
Apr-07-16Resumed JP Morgan Overweight
Apr-07-16Reiterated UBS Buy $366 → $300
Apr-24-17 01:52PM  NASH: The next untapped pharma market gives investors many options Reuters
01:10PM  Trump Executive Order Could Revive Allergan-Pfizer Merger TheStreet.com
09:42AM  3 Healthcare Bargain Stocks You Can Buy Right Now Motley Fool
07:38AM  Novartiss 1Q17 Estimates for Sandoz Market Realist
07:00AM  NASH: The next untapped pharma market gives investors many options Reuters
01:00AM  NASH: The next untapped pharma market gives investors many options Reuters
Apr-23-17 11:41AM  Should Gilead Sciences Be Worried About Allergan? Motley Fool
Apr-21-17 03:28PM  Charlie Munger: Loading Up on Leverage GuruFocus.com
09:00AM  Top Analyst Upgrades and Downgrades: Costco, Dominos Pizza, Fortinet, Verizon, Yum Brands and More 24/7 Wall St.
07:12AM  Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL Zacks
Apr-20-17 04:15PM  Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston PR Newswire
02:15PM  Chapel Hill company partners with Allergan American City Business Journals
09:00AM  Allergan Partners with TARGET PharmaSolutions to Advance NASH Research PR Newswire
Apr-19-17 10:11AM  Allergan (AGN) Collaborates with Novartis to Treat NASH Zacks
07:00AM  [$$] Investors bet on Incyte drug success Financial Times
Apr-18-17 04:51PM  Allergan, Argentum settle patent dispute over eye drug Restasis Reuters
01:15AM  Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration PR Newswire
Apr-17-17 06:33AM  A Healthcare Pick That's Moderately Shielded From Upheaval Morningstar
Apr-13-17 03:40PM  Why Charlie Munger Hates Value Investing GuruFocus.com
09:00AM  Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5) PR Newswire
Apr-12-17 06:03AM  The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17) TheStreet.com
Apr-11-17 07:12PM  Cramer Remix: Why a slew of IPOs might not be a good thin... CNBC Videos
06:53PM  Cramer's charts show these biotechs ignoring their 'polit... CNBC Videos
07:30AM  Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art PR Newswire
Apr-10-17 10:36AM  How Did Allergan Perform in 1Q17? Market Realist
09:00AM  Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency PR Newswire
01:00AM  Takeaways and Observations; Play a Tesla Tune: Doug Kass' Views TheStreet.com
Apr-09-17 03:55PM  Valeant: It's Not a Game of Chess - Part IV GuruFocus.com
Apr-08-17 11:30AM  Allergan is still hopeful about using Botox to treat depression MarketWatch
Apr-07-17 11:00AM  Allergan Teams Up With Media Mogul Wendy Williams to Debut the Patient Empowerment Campaign - Toilet Talk PR Newswire
10:24AM  3 Stocks the Smartest Investors Are Buying Right Now Motley Fool
08:47AM  5 Drug Stocks for Your Portfolio this World Health Day Zacks
Apr-06-17 04:15PM  Allergan Names Daphne Karydas as Senior Vice President of Global Investor Relations & Strategy PR Newswire
01:35PM  Allergan Guilty of Wishful Botox Thinking Bloomberg
11:30AM  Allergan's Botox Studied as Depression Treatment Investopedia
11:29AM  [$$] Investors question Allergan move to test Botox for depression Financial Times
11:18AM  Allergan (AGN) Presents Mixed Depression Data on Botox Zacks
08:31AM  Allergan Plc breached its 50 day moving average in a Bearish Manner : AGN-US : April 6, 2017 Capital Cube
08:22AM  Novartis Licenses ECF843 Eye Drops From Lubris Investopedia
08:00AM  Allergan and ZELTIQ Announce Expiration of Hart-Scott-Rodino Waiting Period for Pending Transaction PR Newswire
Apr-05-17 05:30PM  Allergan to move Botox into late-stage testing for depression Reuters
04:30PM  Allergan Reports Topline Phase II Data Supporting Advancement of BOTOX® (onabotulinumtoxinA) for the Treatment of Major Depressive Disorder (MDD) PR Newswire
04:18PM  Allergan To Test Botox For Depression Despite Mixed Results Forbes
08:00AM  Allergan to Report First Quarter 2017 Earnings and Host Conference Call and Webcast PR Newswire
02:46AM  Why Is Allergan (AGN) Down 2.2% Since the Last Earnings Report? Zacks
Apr-04-17 12:20PM  Paratek shares soar as antibiotic passes late-stage hurdle American City Business Journals
11:14AM  Why Paratek Pharmaceuticals Inc Is Soaring Motley Fool
Mar-31-17 10:36AM  Exploring Eli Lillys Oncology Franchise in 2016
07:21AM  Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK? Zacks
07:00AM  Healthcare: Stock-Picking Increasingly Important as Valuations Rise Morningstar
Mar-30-17 11:45AM  Why Equal Weighted Mutual Funds Scoring Over Index Funds Investopedia
07:27AM  Bill Ackman apologizes for $4 billion Valeant mistake (finally) at MarketWatch
Mar-29-17 06:25PM  Bill Ackman's Insider Trading Lawsuit May Cost Pershing Square Investors $75 Million
05:40PM  Fast Money Madness: Nvidia vs. Allergan
03:47PM  Here's the Bill Ackman apology Wall Street's been waiting for
07:00AM  Market Outlook: Lofty Valuations Call for Careful Stock-Picking at Morningstar
Mar-28-17 04:30PM  Did This Beauty Giant Just Solve The Acne Challenge?
04:09PM  2016s Top Earning Hedge Fund Managers And Their Favorite Stocks at Insider Monkey
11:47AM  Allergan Acne Candidate Meets Endpoints in Phase III Studies
08:15AM  Blog Coverage Allergan and Paratek's Acne Drug Reported Positive Results Accesswire
Mar-27-17 07:00PM  Risk-Reward With Teva Pharmaceutical
06:00PM  Why Impax Labs Soared 37.3% Today at Motley Fool
05:46PM  Health care showdown: Allergan vs. Valeant
05:05PM  DuPont, Impax Labs gain, G-III Apparel slides
01:20PM  Has Allergan's Pullback Ended?
12:41PM  Why Moat Indexes Outperformed Others in February
11:34AM  Allergan, Parateks Acne Drug Succeeds in Phase 3 at Investopedia
11:20AM  Paratek eyes FDA filing as acne drug clears late-stage trials at bizjournals.com
11:20AM  Foamix Acne Drug Fails Late-Stage Study at Investopedia
09:28AM  Skincare Makers Lead Biotech Movers
07:48AM  Allergan, Paratek Pharma report positive results in late-stage trial of acne treatment at MarketWatch
07:36AM  Vyzulta May Be a Potent Therapy for Glaucoma in the Future
07:31AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne PR Newswire
07:30AM  Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne GlobeNewswire
Mar-26-17 11:01AM  3 Great Stocks to Buy in a Market Pullback at Motley Fool
Mar-24-17 02:00PM  Can Anyone Challenge Allergan In Medical-Aesthetics Market?
07:35AM  Valeant Pharmaceuticals is Developing its Sales Force
01:00AM  After Trump rally, equity investors move into healthcare, retailers Reuters
Mar-23-17 06:31PM  The Most Attractive Value Stock There Is?
11:24AM  Insys Therapeutics' Syndros Gets Final DEA Rule at Investopedia
10:19AM  Allergan's Restasis Now Available in Multidose Bottle in U.S.
09:20AM  Buyback ETF Steady As Repurchases Decline
09:06AM  Teva Denies Reports About 11% Global Workforce Reduction (TEVA) at Investopedia
08:59AM  The Supreme Court could fundamentally change America's broken patent system
Mar-22-17 06:45PM  Companies Spend Less on Share Buybacks for Second Year in 2016
04:35PM  Allergan, Dow's Apple Lead Q4 Buybacks; Health Care Atop S&P 500
02:52PM  Allergan Stock Reacts Well In Downtrodden Sector at Investopedia
10:30AM  Latest Editas research pact could be worth up to $1 billion at bizjournals.com
07:31AM  Allergan Announces Availability of RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) 0.05% -- the First FDA-Approved Preservative Free Prescription Eye Drop Available in a Multidose Bottle PR Newswire
Mar-21-17 05:35PM  David Tepper Takes Big Risks for Big Rewards
05:26PM  FDA Links Breast Implants To A Rare Form Of Cancer
02:58PM  Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
Mar-20-17 04:51PM  Editas Get A Vetr Upgrade To Strong Buy
01:53PM  Allergan Is Setting Up Nicely for a Possible Move at Investopedia
07:31AM  JUVÉDERM VOLLURE XC Approved by U.S. FDA for Correction of Facial Wrinkles and Folds in Adults over the Age of 21 PR Newswire
Mar-17-17 09:27AM  Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded
Mar-16-17 03:36PM  Valeant: Yes, Ackman's a Loser. But How Much Did Short Sellers Make? at Barrons.com
12:35PM  Court allows Allergan shareholders to go after Ackman, Valeant as a class at bizjournals.com
06:11AM  When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)
Mar-15-17 07:15PM  How to maneuver CEO buybacks
Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BISARO PAULDirectorMar 02Sale246.6870,00017,267,561235,900Mar 06 06:59 AM
Meury WilliamChief Commercial OfficerDec 08Option Exercise109.1211,8071,288,38048,866Feb 14 09:13 PM
Basgoz NesliDirectorDec 08Sale188.7250094,3605,515Dec 09 05:56 PM
SAUNDERS BRENT LCEO and PresidentNov 21Buy189.135,250992,941106,564Nov 21 04:03 PM
Hilado Maria TeresaChief Financial OfficerNov 11Buy210.641,422299,53613,379Nov 15 05:18 PM
ADBE Adobe Systems Incorporated daily Stock Chart
ADBE [NASD]
Adobe Systems Incorporated
IndexS&P 500 P/E50.86 EPS (ttm)2.61 Insider Own0.10% Shs Outstand494.61M Perf Week2.23%
Market Cap65.73B Forward P/E26.67 EPS next Y4.98 Insider Trans-51.58% Shs Float493.06M Perf Month4.75%
Income1.31B PEG3.16 EPS next Q0.95 Inst Own88.90% Short Float1.01% Perf Quarter19.75%
Sales6.15B P/S10.68 EPS this Y86.70% Inst Trans0.30% Short Ratio2.15 Perf Half Y21.88%
Book/sh15.34 P/B8.66 EPS next Y26.15% ROA10.40% Target Price143.85 Perf Year40.19%
Cash/sh9.40 P/C14.14 EPS next 5Y16.11% ROE17.80% 52W Range90.35 - 131.99 Perf YTD29.08%
Dividend- P/FCF29.29 EPS past 5Y7.00% ROI13.20% 52W High0.68% Beta1.03
Dividend %- Quick Ratio1.90 Sales past 5Y6.80% Gross Margin86.00% 52W Low47.08% ATR1.65
Employees15706 Current Ratio1.90 Sales Q/Q21.60% Oper. Margin26.90% RSI (14)78.99 Volatility0.85% 1.08%
OptionableYes Debt/Eq0.25 EPS Q/Q58.20% Profit Margin21.30% Rel Volume0.79 Prev Close131.52
ShortableYes LT Debt/Eq0.25 EarningsMar 16 AMC Payout0.00% Avg Volume2.32M Price132.89
Recom1.80 SMA202.41% SMA506.90% SMA20021.34% Volume1,845,335 Change1.04%
Apr-13-17Initiated Guggenheim Buy
Apr-12-17Initiated Stifel Buy $150
Mar-24-17Upgrade Credit Suisse Neutral → Outperform
Mar-17-17Upgrade Wunderlich Hold → Buy
Mar-17-17Reiterated RBC Capital Mkts Outperform $130 → $135
Mar-17-17Reiterated Pivotal Research Group Hold $104 → $109
Mar-17-17Reiterated BMO Capital Markets Outperform $125 → $140
Feb-28-17Resumed Robert W. Baird Outperform $125 → $130
Feb-08-17Reiterated RBC Capital Mkts Outperform $115 → $125
Jan-12-17Downgrade Pivotal Research Group Buy → Hold $136 → $104
Jan-11-17Initiated Wells Fargo Market Perform
Jan-05-17Initiated BMO Capital Markets Outperform $125
Nov-03-16Reiterated Wunderlich Hold $99 → $115
Sep-21-16Reiterated RBC Capital Mkts Outperform $115 → $116
Sep-21-16Reiterated Pivotal Research Group Buy $124 → $125
Jul-26-16Initiated Piper Jaffray Overweight $125
Jun-22-16Reiterated UBS Buy $114 → $122
Jun-22-16Reiterated Rosenblatt Buy $112 → $120
Apr-21-16Resumed Credit Suisse Neutral $85 → $105
Apr-12-16Reiterated FBR Capital Mkt Perform $100 → $115
Apr-22-17 10:15AM  Oracle's Latest Acquisition Shows the Ad Software Arms Race Remains in Full Swing TheStreet.com
Apr-21-17 10:39AM  Top Ranked Growth Stocks to Buy for April 21st Zacks
Apr-20-17 08:22AM  Colgate, Adobe, and 2 More Are Ready to Rip Higher This Spring TheStreet.com
Apr-19-17 02:28PM  Adobe Creative Cloud Propels Video Forward at NAB 2017 Business Wire
09:00AM  Adobe Named a Leader in Gartner Magic Quadrant for Multichannel Campaign Management Business Wire
Apr-17-17 12:45PM  ETFs with exposure to Adobe Systems, Inc. : April 17, 2017 Capital Cube
07:56AM  Adobe (ADBE) Up 5.5% Since Earnings Report: Can It Continue? Zacks
Apr-13-17 01:34PM  Guggenheim: Adobe could rally 20% CNBC Videos
09:17AM  3 Best Stocks for Your Roth IRA Motley Fool
08:21AM  Early movers: JPM, PNC, AAPL, DIS, GS, WFC, TSLA, SEAS & more CNBC
Apr-12-17 12:34PM  10 Companies That Offer The Best Paid Paternity Leave Benefits Insider Monkey
11:05AM  Analysts' Actions -- Lululemon, L Brands, Masco, Under Armour and More TheStreet.com
Apr-11-17 11:00AM  A new app could solve the biggest problems with selfies Business Insider
Apr-10-17 12:39PM  Virtual Reality Storytellers Are Ready To Get Into Your Headset Forbes
12:06PM  Splunk's Move to Subscriptions Could Signal Huge Gains for the Stock Motley Fool
Apr-08-17 09:35AM  Big Tech and Biotech Trades Highlight Insider Selling: Gap, Adobe, Celgene, Splunk and More 24/7 Wall St.
Apr-07-17 09:00AM  Adobe Named the Leader Among Digital Intelligence Platform Vendors by Independent Research Firm Business Wire
Apr-05-17 04:27PM  7 Stocks Beating the Market GuruFocus.com
04:14PM  ETFs with exposure to Adobe Systems, Inc. : April 5, 2017 Capital Cube
09:41AM  Adobe Is Going All In on AI Motley Fool
Apr-04-17 04:23PM  3 Cloud Computing Stocks To Buy Right Now Zacks
09:25AM  Adobe Systems, Inc. :ADBE-US: Earnings Analysis: Q1, 2017 By the Numbers : April 4, 2017 Capital Cube
Mar-31-17 11:36AM  Stocks set to post best Q1 in 4 years Yahoo Finance
Mar-30-17 01:56PM  Adobe Tests AI-Driven Photo Retouching Tool at Investopedia
Mar-29-17 04:14PM  ADOBE SYSTEMS INC Files SEC form 10-Q, Quarterly Report
02:31PM  Stocks Mixed, Nasdaq Up; Can These 6 Names Become 'The Next Cisco' Of 2010s? Investor's Business Daily
08:15AM  Post Earnings Coverage as Adobe Reported Record Breaking Quarter; Revenue Gew 22% and Adjusted EPS Soared 42% Accesswire
Mar-28-17 07:47PM  Many of Silicon Valley's biggest companies are absent from San Jose flood-relief efforts at bizjournals.com
07:47PM  Many of Silicon Valley's biggest companies are absent from San Jose flood-relief efforts American City Business Journals
08:54AM  Is Adobe Systems Getting Ready for Another Jump Higher? TheStreet.com
08:32AM  Looking for a Top Momentum Stock? 3 Reasons Why Adobe Systems (ADBE) is a Great Choice Zacks
Mar-27-17 04:09PM  Trader tracker: Q1's most memorable calls at CNBC
01:51PM  Adobe Price Estimate Revised To $132, Here's Why at Forbes
11:05AM  Jim Cramer: We Like Adobe for Action Alerts PLUS at TheStreet
10:20AM  Merrill Lynch Out With Revised 6 Top Software Stock Picks to Buy Now 24/7 Wall St.
09:31AM  Zacks.com featured highlights: CBRE Group, Wabash National, Honda Motor, Universal Forest Products and Adobe Systems
08:52AM  Adobe (ADBE) Stock Gains as Credit Suisse Ups Price Target
08:49AM  Looking for a Growth Stock? Why It is Time to Focus on Adobe Systems (ADBE)
08:26AM  Analysts' Actions -- Adobe, Starbucks, Snap, KB Home and More
12:06AM  [$$] Why PTCs Revenue Still Raises Eyebrows at The Wall Street Journal
Mar-26-17 04:40PM  How Adobe Can Plug the Hole in Its Cloud at TheStreet
09:27AM  3 of the Safest Stocks You Can Buy Right Now at Motley Fool
09:22AM  [$$] Why PTC's Revenue Still Raises Eyebrows at The Wall Street Journal
Mar-25-17 10:40AM  Massive Biotech Trade Highlights Insider Selling: Esperion Therapeutics, Adobe, Hilton, Fresh Del Monte and More
Mar-24-17 04:13PM  Apple, Adobe Price Targets Hiked; Under Armour, Micron Upgraded
03:42PM  Stocks Mixed on Reports Health Care Bill Has Been Pulled
12:15PM  Adobe Systems Stock Rising on Credit Suisse Upgrade at TheStreet
11:06AM  Microsoft and Adobe Flat as Companies Integrate Sales and Marketing Data Gurufocus
10:59AM  Stocks Higher as Trump Faces a Test on the Health Care Vote
10:48AM  7 Stocks to Buy with Impressive Interest Coverage Ratio
10:23AM  Tech Today: Micron Surges, GameStop Drops, Even More Apple Plaudits at Barrons.com
08:32AM  Analysts' Actions -- Adobe, Macy's, Roper, Under Armour and More
12:22AM  [$$] High-Court Case to Challenge Jurisdiction Shopping in Patent Suits at The Wall Street Journal
Mar-23-17 05:40PM  How Adobe Can Plug the Holes in Its Cloud at TheStreet
08:08AM  Watch now: BizWireTV Brings You the Richest People in the World Find Out Who Made the Cut, and Shopping Tech as Easy as Asking for What You Want Business Wire
06:22AM  [video]Starbucks: Cramer's Top Takeaways
05:30AM  [$$] How a Patent Case May Shake Up Domination of Eastern Texas at The Wall Street Journal
Mar-22-17 11:19PM  Adobe is Piecing Together Different Parts of Its Marketing Software Empire
07:36PM  Adobe CEO on Microsoft Partnership, A.I. and M&A
07:36PM  Adobe CEO on Microsoft Partnership, A.I. and M&A at Bloomberg
07:28PM  Adobe CEO Focused on Microsoft Partnership and A.I.
07:28PM  Adobe CEO Focused on Microsoft Partnership and A.I. at Bloomberg
06:39PM  Markets Subdued as Trump Trade Slumps: Cramer's 'Mad Money' Recap (Wednesday 3/22/17)
04:40PM  Indexes inch back upward as tech stocks rise; Nike plunges
03:18PM  Is Adobe Still a Buy After 22% Gains? at Investopedia
02:38PM  Adobe Unveils New Enterprise Cloud Solution at Investopedia
11:59AM  Top Research Reports for Netflix, Goldman Sachs & Kinder Morgan
09:00AM  AI, VR, IoT and Kate McKinnon Headline Adobe Summit Sneaks Business Wire
07:35AM  Salesforce Gives Microsoft Another Reason to Worry at Market Realist
Mar-21-17 07:44PM  Adobe Redefines Customer Experience at Adobe Summit 2017 Business Wire
04:50PM  Adobe, Microsoft Join Forces In Sales, Marketing Software
04:25PM  Transform into an 'experience business' or die: 4 tips from Adobe
04:00PM  Microsoft teams up with Adobe to take on Salesforce, Oracle at bizjournals.com
10:43AM  Microsoft Collaborates with Adobe to Gain CRM Dominance
10:15AM  Apple unveils (RED) iPhone, Walmart's new startup, Adobe and Microsoft join forces
10:02AM  Adobe tightens Microsoft ties in fight with Salesforce, Oracle at bizjournals.com
08:31AM  Microsoft, Adobe make some progress on their joint cloud commitments at ZDNet
08:16AM  State of the Trump stock market rally
07:26AM  Microsoft, Adobe Team Up to Provide Businesses Joint Solutions at Investopedia
06:20AM  Heres Why Microsoft, Apple, Adobe Systems, Alphabet, and More Are Trending at Insider Monkey
12:01AM  Adobe launches Experience Cloud aims to bridge from marketing to more parts of the enterprise at ZDNet
12:00AM  Adobe Unveils New Cloud Platform Capabilities Business Wire
12:00AM  Adobe Unveils Adobe Advertising Cloud Business Wire
12:00AM  Adobe Launches Adobe Experience Cloud Business Wire
12:00AM  Adobe is now officially an ad tech company Business Insider
12:00AM  Adobe and Microsoft Announce Availability of Joint Offerings to Transform Customer Experiences Business Wire
Mar-20-17 11:45PM  Adobe, Microsoft team up to share sales and marketing data Reuters
07:51PM  3 Stocks We're Watching in the First Quarter at Motley Fool
04:39PM  US stock indexes dip for a third day as banks stumble AP
10:10AM  Company News for March 20, 2017
09:30AM  Zacks Investment Ideas feature highlights: Oracle and Adobe Systems
04:09AM  [$$] Adobe Target Jacked Up to $145 at Barrons.com
01:00AM  Slow Day for the Market; Adobe Builds Next Step in Tech Surge: Jim Cramer's View
Mar-17-17 07:01PM  Cramer: Nothing to See in This Market, Move Along
04:45PM  Stock market slides at close but holds on to weekly gains at MarketWatch
04:41PM  S&P 500 limps to the finish line in another winning week AP
04:40PM  Week In Review: Fed Hikes, Intel Buys Mobileye, Software Earnings Boom, IPOs Strong
04:33PM  Why Amazon May Look Less Appealing; Netflix, Adobe See Action
04:30PM  Why Adobe Systems, NantHealth, and Smart Sand Jumped Today at Motley Fool
04:22PM  Indexes End Mostly Flat; Tiffany Sparkles; Strong Debut For MuleSoft
Adobe Systems Incorporated operates as a diversified software company worldwide. Its Digital Media segment provides tools and solutions that enable individuals, small and medium businesses, and enterprises to create, publish, promote, and monetize their digital content. This segment's flagship product is Creative Cloud, a subscription service that allows customers to download and install the latest versions of its creative products. This segment serves traditional content creators, Web application developers, and digital media professionals, as well as their management in marketing departments and agencies, companies, and publishers. The company's Digital Marketing segment offers solutions for how digital advertising and marketing are created, managed, executed, measured, and optimized. This segment provides analytics, social marketing, targeting, advertising and media optimization, digital experience management, cross-channel campaign management, and audience management solutions, as well as video delivery and monetization to digital marketers, advertisers, publishers, merchandisers, Web analysts, chief marketing officers, chief information officers, and chief revenue officers. Its Print and Publishing segment offers products and services, such as eLearning solutions, technical document publishing, Web application development, and high-end printing, as well as publishing needs of technical and business, and original equipment manufacturers (OEMs) printing businesses. The company markets and licenses its products and services directly to enterprise customers through its sales force, as well as to end-users through app stores and through its Website at adobe.com. It also distributes products and services through a network of distributors, value-added resellers, systems integrators, independent software vendors, retailers, and OEMs. The company was founded in 1982 and is headquartered in San Jose, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lewnes AnnEVP, Chief Marketing OfficerApr 12Sale129.962,233290,20166,410Apr 13 04:17 PM
DALEY JAMES EDirectorApr 11Option Exercise0.002,801030,887Apr 13 04:14 PM
Banse AmyDirectorApr 11Option Exercise0.002,801030,592Apr 13 04:12 PM
Desmond LauraDirectorApr 11Option Exercise0.002,801023,852Apr 13 04:14 PM
GESCHKE CHARLES MDirectorApr 11Option Exercise0.002,8010172,024Apr 13 04:15 PM
ROSENSWEIG DANIELDirectorApr 11Option Exercise0.002,801015,801Apr 13 04:15 PM
BARNHOLT EDWARD WDirectorApr 11Option Exercise0.002,801035,925Apr 13 04:13 PM
BURGESS ROBERT KDirectorApr 11Option Exercise0.002,801039,925Apr 13 04:13 PM
CALDERONI FRANKDirectorApr 11Option Exercise0.002,801023,852Apr 13 04:14 PM
LAMKIN BRYANEVP & GM, Digital MediaMar 31Sale130.3020,0002,605,95052,083Mar 31 07:29 PM
Lewnes AnnEVP, Chief Marketing OfficerMar 22Sale125.002,233279,12568,643Mar 24 04:05 PM
GESCHKE CHARLES MDirectorMar 20Sale125.9559,5507,500,060169,223Mar 21 04:25 PM
LAMKIN BRYANEVP & GM, Digital MediaMar 15Option Exercise0.0019,750082,388Mar 17 04:27 PM
GARRETT MARKEVP, CFO & Asst. SecretaryFeb 06Sale114.1245,1995,158,0864,339Feb 07 04:10 PM
BURGESS ROBERT KDirectorFeb 02Option Exercise42.6125,0001,065,25062,124Feb 03 04:11 PM
BURGESS ROBERT KDirectorFeb 02Sale113.1925,0002,829,71037,124Feb 03 04:11 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryJan 27Sale113.0810,4401,180,54447,482Jan 27 04:14 PM
Rencher BradleyEVP & GM, Digital MarketingJan 25Sale113.9640,0004,558,27650,735Jan 26 04:14 PM
THOMPSON MATTHEWEVP WW Field OperationsJan 25Sale113.7855,0006,257,92851,919Jan 26 04:14 PM
NARAYEN SHANTANUPresident and CEOJan 25Sale113.91173,70319,787,246299,243Jan 26 04:13 PM
Rencher BradleyEVP & GM, Digital MarketingJan 24Option Exercise0.0080,7200101,620Jan 26 04:14 PM
ROWLEY RICHARDVP, Corp. Controller & CAOJan 24Option Exercise0.0013,748010,098Jan 26 04:14 PM
THOMPSON MATTHEWEVP WW Field OperationsJan 24Option Exercise0.00113,7560131,387Jan 26 04:14 PM
LAMKIN BRYANEVP & GM, Digital MediaJan 24Option Exercise0.0080,153078,016Jan 26 04:12 PM
Lewnes AnnEVP, Chief Marketing OfficerJan 24Option Exercise0.0056,620080,588Jan 26 04:12 PM
Morris DonnaEVP, Cust. & Emp. ExperienceJan 24Option Exercise0.0056,620089,524Jan 26 04:13 PM
NARAYEN SHANTANUPresident and CEOJan 24Option Exercise0.00363,2400549,812Jan 26 04:13 PM
Parasnis AbhayEVP & CTOJan 24Option Exercise0.008,16508,436Jan 26 04:13 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryJan 24Option Exercise0.0056,036068,744Jan 26 04:12 PM
GARRETT MARKEVP, CFO & Asst. SecretaryJan 24Option Exercise0.00103,587071,082Jan 26 04:12 PM
DALEY JAMES EDirectorJan 20Option Exercise33.2310,000332,30038,086Jan 23 04:58 PM
DALEY JAMES EDirectorJan 20Sale110.0210,0001,100,20028,086Jan 23 04:58 PM
WARNOCK JOHN ECo-Chairman of the BoardJan 17Sale107.285,000536,405559,600Jan 17 04:14 PM
GESCHKE CHARLES MCo-Chairman of the BoardJan 09Sale108.5223,1002,506,775228,773Jan 09 06:24 PM
ROWLEY RICHARDVP, Corp. Controller & CAOJan 06Sale108.131,348145,7600Jan 06 06:54 PM
GESCHKE CHARLES MCo-Chairman of the BoardJan 04Sale104.0348,1005,003,800251,873Jan 05 04:20 PM
WARNOCK JOHN ECo-Chairman of the BoardDec 19Sale105.416,000632,472565,600Dec 21 04:43 PM
Morris DonnaEVP, Cust. & Emp. ExperienceOct 10Sale110.0010,0001,100,00054,279Oct 11 04:43 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryOct 10Sale109.6413,3311,461,57930,993Oct 11 04:41 PM
WARNOCK JOHN ECo-Chairman of the BoardSep 27Sale106.995,000534,950571,600Sep 27 04:49 PM
ROSENSWEIG DANIELDirectorSep 26Sale107.4213,0001,396,4266,268Sep 27 04:47 PM
DALEY JAMES EDirectorSep 22Option Exercise33.236,276208,55134,362Sep 23 05:00 PM
DALEY JAMES EDirectorSep 22Sale108.006,276677,80828,086Sep 23 05:00 PM
GARRETT MARKEVP, CFO & Asst. SecretarySep 06Sale103.4726,8992,783,3120Sep 06 07:01 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryAug 29Sale101.855,450555,08344,324Aug 29 06:11 PM
Lewnes AnnEVP, Chief Marketing OfficerAug 26Sale101.6813113,32042,968Aug 29 04:29 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryAug 23Option Exercise0.0027,500064,123Aug 24 04:08 PM
GARRETT MARKEVP, CFO & Asst. SecretaryAug 16Option Exercise0.0056,250056,250Aug 17 04:31 PM
Morris DonnaEVP, Cust. & Emp. ExperienceAug 10Option Exercise34.032,33579,46076,614Aug 11 04:05 PM
Morris DonnaEVP, Cust. & Emp. ExperienceAug 10Sale100.0010,0001,000,00064,279Aug 11 05:06 PM
Morris DonnaEVP, Cust. & Emp. ExperienceAug 10Sale100.002,335233,50074,279Aug 11 04:05 PM
Lewnes AnnEVP, Chief Marketing OfficerJul 29Sale98.404,000393,60043,099Aug 01 04:09 PM
DALEY JAMES EDirectorJul 20Option Exercise33.235,000166,15033,086Jul 21 04:08 PM
WARNOCK JOHN ECo-Chairman of the BoardJul 20Sale98.512,000197,024579,115Jul 21 04:10 PM
DALEY JAMES EDirectorJul 20Sale98.505,000492,50028,086Jul 21 04:08 PM
BARNHOLT EDWARD WDirectorJul 11Option Exercise37.0925,000927,25058,124Jul 11 05:56 PM
BARNHOLT EDWARD WDirectorJul 11Sale97.2525,0002,431,13333,124Jul 11 05:56 PM
Rencher BradleyEVP & GM, Digital MarketingJul 01Sale95.4637,5623,585,62747,269Jul 01 05:38 PM
ROWLEY RICHARDVP, Corp. Controller & CAOJul 01Sale95.6827125,9291,348Jul 01 04:13 PM
LAMKIN BRYANEVP & GM, Digital MediaJul 01Sale95.049,616913,90523,665Jul 01 04:10 PM
WARNOCK JOHN ECo-Chairman of the BoardJun 30Sale95.154,000380,605581,115Jul 01 04:09 PM
ROSENSWEIG DANIELDirectorJun 29Sale92.9819,3001,794,57419,268Jul 11 04:57 PM
Lewnes AnnEVP, Chief Marketing OfficerJun 24Sale92.394,000369,56046,828Jun 24 04:32 PM
Lewnes AnnEVP, Chief Marketing OfficerMay 27Sale99.404,000397,59650,828May 31 04:09 PM
DILLON MICHAEL AEVP, Gen. Counsel & SecretaryMay 10Sale95.099,466900,16736,409May 11 04:17 PM
Lewnes AnnEVP, Chief Marketing OfficerApr 29Sale92.894,000371,56054,828May 02 04:29 PM
SHPG Shire plc daily Stock Chart
SHPG [NASD]
Shire plc
Index- P/E63.64 EPS (ttm)2.76 Insider Own0.10% Shs Outstand301.46M Perf Week2.26%
Market Cap52.97B Forward P/E10.18 EPS next Y17.26 Insider Trans0.00% Shs Float181.89M Perf Month0.97%
Income603.50M PEG5.51 EPS next Q3.30 Inst Own23.20% Short Float0.60% Perf Quarter8.16%
Sales11.40B P/S4.65 EPS this Y-65.50% Inst Trans0.06% Short Ratio1.09 Perf Half Y-6.28%
Book/sh96.08 P/B1.83 EPS next Y14.89% ROA0.60% Target Price238.85 Perf Year-4.62%
Cash/sh1.80 P/C97.66 EPS next 5Y11.55% ROE1.30% 52W Range160.40 - 208.32 Perf YTD3.57%
Dividend0.91 P/FCF- EPS past 5Y-12.80% ROI2.10% 52W High-15.65% Beta1.63
Dividend %0.52% Quick Ratio0.50 Sales past 5Y22.30% Gross Margin66.50% 52W Low9.55% ATR2.61
Employees23906 Current Ratio1.00 Sales Q/Q121.80% Oper. Margin8.40% RSI (14)53.15 Volatility1.34% 1.31%
OptionableYes Debt/Eq0.79 EPS Q/Q7.20% Profit Margin2.90% Rel Volume0.73 Prev Close171.94
ShortableYes LT Debt/Eq0.69 EarningsMay 02 BMO Payout0.00% Avg Volume992.84K Price175.71
Recom1.70 SMA201.47% SMA50-0.24% SMA200-2.88% Volume723,968 Change2.19%
Mar-09-17Initiated Liberum Buy
Dec-02-16Initiated Societe Generale Buy
Sep-26-16Downgrade HSBC Securities Buy → Hold
Jun-03-16Reiterated Jefferies Buy $223 → $262
May-26-16Initiated Stifel Buy $230
May-06-16Initiated Liberum Buy
Feb-26-16Initiated Cantor Fitzgerald Buy
Feb-10-16Upgrade RBC Capital Mkts Sector Perform → Outperform $240 → $240
Feb-10-16Initiated Guggenheim Neutral
Jan-15-16Upgrade BofA/Merrill Neutral → Buy
Jan-12-16Upgrade Credit Suisse Neutral → Outperform
Jan-12-16Reiterated RBC Capital Mkts Sector Perform $248 → $240
Nov-17-15Upgrade Leerink Partners Mkt Perform → Outperform $239
Nov-03-15Upgrade HSBC Securities Hold → Buy
Oct-26-15Reiterated RBC Capital Mkts Sector Perform $263 → $248
Oct-14-15Initiated Northland Capital Outperform $288
Sep-30-15Upgrade HSBC Securities Reduce → Hold
Aug-06-15Downgrade Exane BNP Paribas Outperform → Neutral
Jul-16-15Resumed Berenberg Buy
Apr-29-15Initiated Exane BNP Paribas Outperform
Apr-24-17 01:00AM  Shire Launches #PIPostsThanks Social Campaign to Raise Awareness of Primary Immunodeficiency (PI) PR Newswire
Apr-17-17 01:00AM  Shire plc: Data Show A Bleeding Episode Occurs Every Three to 15 Seconds in People Living With Hemophilia Worldwide PR Newswire
Apr-10-17 07:00AM  PatientsLikeMe and Shire Pharmaceuticals Collaborate to Study Rare Genetic Diseases Business Wire
Apr-06-17 08:22AM  Novartis Licenses ECF843 Eye Drops From Lubris Investopedia
Apr-04-17 11:12AM  Shire Plc : SHPG-US: Dividend Analysis : March 10th, 2017 (record date) : By the numbers : April 4, 2017 Capital Cube
Apr-03-17 01:48PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Mar-30-17 04:41AM  INTUNIV® (Guanfacine Hydrochloride Prolonged Release), a Non-stimulant for the Treatment of ADHD, Receives Approval in Japan PR Newswire
Mar-28-17 04:50PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-27-17 01:32PM  Shire: Can It Pay Down Debt? Barrons.com
Mar-23-17 05:03PM  Shire (SHPG) Rare Disease Drug Gets Fast Track Designation Zacks
Mar-22-17 10:27AM  Shire hTTP Drug Secures Fast Track Designation Investopedia
07:00AM  Shire Receives FDA Fast Track Designation for Recombinant ADAMTS13 (SHP655) for Treatment of Hereditary Thrombotic Thrombocytopenic Purpura PR Newswire
Mar-21-17 09:55AM  Is Shire Stock a Good Choice for Value Investors Now? Zacks
Mar-16-17 07:14PM  Shire's (SHPG) Cinryze Label Expanded for Pediatric Use Zacks
10:40AM  Shires Cinryze Drug Gets EU Label Expansion Investopedia
02:00AM  Shire Receives European Approval for Label Extension of CINRYZE®(C1 inhibitor ) to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Paediatric Patients with HAE PR Newswire
Mar-13-17 02:50PM  Whats that thing on top of the Sanofi-Genzyme building anyway? at bizjournals.com
02:31PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-10-17 04:25PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:20PM  Biogen Spinoff Takes Flight With Focus On Hemophilia Drugs
Mar-09-17 08:49AM  Coverage initiated on Shire plc by Liberum
Mar-07-17 12:48PM  European Stocks Mixed as Frankfurt Rises, Paris Falls
Mar-06-17 01:55PM  CUVITRU Data Demonstrate Improved Treatment Satisfaction Relative to Patients' Previous Immunoglobulin Therapy PR Newswire
Mar-03-17 12:34PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Mar-02-17 05:08PM  Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
12:34PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
12:12PM  These 3 Big Pharma Stocks Are Exceptionally Cheap at Motley Fool
Mar-01-17 05:02PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Shire to Participate at the Cowen 37th Annual Healthcare Conference PR Newswire
Feb-28-17 01:04PM  SHIRE PLC Financials
09:55AM  Amicus Therapeutics Launches Galafold in UK at Investopedia
Feb-27-17 06:00AM  Drugmakers Eye $35B Market Amid Obesity Crisis at Investopedia
01:01AM  argenx announces extension of therapeutic antibody alliance with Shire GlobeNewswire
Feb-24-17 04:42PM  SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:21PM  NASH Is Todd Hagopian's Top Biotech Sub-Sector For 2017 at Forbes
10:02AM  Patient Dies In Roche Hemophilia Study at Investopedia
08:15AM  Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer Accesswire
07:17AM  CHMP Recommends EU Conditional Marketing Authorisation for Natpar® (Parathyroid Hormone) for Patients with Chronic Hypoparathyroidism PR Newswire
Feb-23-17 09:20AM  Biotech Movers: Shire Rises on Encouraging Angioedema Results
04:11AM  New England Journal of Medicine Publishes Phase 1b Results for Shire's Investigational Treatment for Hereditary Angioedema, a Rare Genetic Disease PR Newswire
02:00AM  Shire Launches 'Rare Count' Campaign to Personalize the Global Impact of Rare Diseases PR Newswire
Feb-22-17 04:56PM  SHIRE PLC Files SEC form 10-K, Annual Report
03:13PM  Momenta Tops Q4 Earnings, Shares Down on Warning Letter
11:55AM  Shire Plc :SHPG-US: Earnings Analysis: 2016 By the Numbers : February 22, 2017
11:05AM  Momenta 4Q Net 60 Cents a Share at Investopedia
Feb-21-17 02:01PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
09:27AM  Shire Plc :SHPG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017
Feb-20-17 09:57AM  3 Stocks to Invest in Big Pharma at Motley Fool
Feb-17-17 02:04PM  Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View
01:50PM  Shire PLC 4Q Earnings, Revenue Beat Street at Investopedia
01:08PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Feb-16-17 04:28PM  Drugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High
08:14AM  Shire beats Street 4Q forecasts
07:52AM  Shire Reports Full Year 2016 Results With Record Revenue; Positioned for Continued Strong Growth Driven by Best-in-class Rare Disease Pipeline PR Newswire
07:25AM  Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth
Feb-15-17 04:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
12:49PM  Amicus Therapeutics Updates Migalastat Drug at Investopedia
Feb-14-17 07:30AM  Shire to Highlight Advancements in Rare Genetic Diseases PR Newswire
Feb-08-17 10:04AM  Shire ViroPharma Sued By FTC Over Sham FDA Filings at Investopedia
Feb-07-17 04:05PM  FTC says Shire unit used illegal tactics to block generic competition at bizjournals.com
03:42PM  Shire Responds to U.S. Federal Trade Commission Civil Action PR Newswire
10:45AM  Hemophilia Drug Market Competitive Ramps Up at Investopedia
Feb-02-17 10:40AM  5 Drugmakers Battle Over the $10 Billion Hemophilia Market at Motley Fool
Feb-01-17 03:49PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
01:39PM  New Data From Shire Aim to Help Close the Diagnosis and Treatment Gap for People With Hemophilia PR Newswire
Jan-27-17 12:20PM  Keeley All Cap Value Fund Comments on Shire
Jan-26-17 08:25AM  Drug Giants May Benefit From China Drug Inclusion at Investopedia
Jan-25-17 01:10PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-23-17 11:27AM  5 Stupendously Expensive Cancer Drugs at Motley Fool
Jan-20-17 05:50PM  Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA
Jan-19-17 10:00AM  Is Shire plc a Great Stock for Value Investors?
07:00AM  U.S. FDA Acknowledges Receipt of Shire's New Drug Application for SHP465 for ADHD PR Newswire
Jan-18-17 12:37PM  Alcobra Stock Down on Poor Late-Stage Data on ADHD Drug
Jan-17-17 12:24PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Jan-13-17 11:56AM  FTSE 100 continues record run, rising for 14th day in a row at MarketWatch
Jan-12-17 02:34PM  KemPharm CEO On Recent Results, Catalysts And Prospects: 'ADHD Is By Far The Larger Market Opportunity'
02:00PM  Lawsuit accuses Shire of monopolizing market for ADHD drug at bizjournals.com
12:20PM  Drug makers, auto stocks yank European stocks lower for first time in 3 days at MarketWatch
Jan-11-17 08:23PM  PRESS DIGEST- Financial Times - Jan 12 Reuters
04:32PM  [$$] Shire to Pay $350 Million to Settle Dermagraft Kickback Allegations at The Wall Street Journal
02:45PM  Pharmaceutical company agrees to landmark settlement in Tampa federal court at bizjournals.com
01:40PM  Trump slams drug industry at press conference, sending biotech stocks tumbling at bizjournals.com
12:21PM  FTSE 100 logs 10th day of all-time highs at MarketWatch
Jan-10-17 01:17PM  Shire CEO: Our innovation score is very high
Jan-09-17 05:35PM  Martin Whitman Invests in Homebuilder in 4th Quarter
01:55PM  Merrimack Pharma to Sell Cancer Drugs for $1B at Investopedia
Jan-06-17 04:22PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
10:46AM  For Shire PLC (ADR) (SHPG) Securing Hemophilia Market With Long Acting Version Is Crucial at Insider Monkey
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com
12:52PM  Cooperman's best ideas: 14 stock picks
12:03PM  Billionaire James Dinan Betting On These Stocks To Recover Losses at Insider Monkey
Jan-04-17 05:14PM  SHIRE PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
09:30AM  Shire to Present at the 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Jan-03-17 05:31PM  SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits
Dec-30-16 06:17AM  Pharma Stock Roundup: Cempra Plunges to 52-Week Low, Shire Drug Label Expanded
Dec-28-16 10:18AM  Shire Gets FDA Approval for Label Expansion of Adynovate
08:15AM  Blog Coverage Shire Receives FDA Approval for ADYNOVATE for Use in Children Under 12 Years Accesswire
Dec-27-16 07:00AM  Shire Announces FDA Approval of Adynovate® for use in Children and Surgical Settings PR Newswire
06:00AM  Most Important Mergers and Acquisitions of 2016 at Investopedia
Dec-23-16 05:12PM  Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4
Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/VENVANSE, a pro-drug stimulant; ELVANSE/TYVENSE; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist for oral symptomatic treatment of chronic constipation in women. In addition, it offers FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; and XAGRID for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients, as well as for the treatment of thrombocythemia. Further, the company provides REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR for the symptomatic treatment of acute attacks of hereditary angioedema. Additionally, it offers FOSRENOL for the treatment of hyperphosphatemia in end stage renal disease; XAGRID for the reduction of elevated platelet counts; and CINRYZE, a C1 esterase inhibitor therapy for routine prophylaxis against hereditary angioedema. The company also licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. Shire plc markets its products directly to government hospitals, clinics, pharmacies, and other agencies; and through wholesalers and distributors. The company sells its products in North America, the United Kingdom, the Republic of Ireland, and internationally. Shire plc has research collaboration with Santaris Pharma A/S. The company was founded in 1986 and is headquartered in Dublin, Ireland.